{"protocolSection":{"identificationModule":{"nctId":"NCT05842967","orgStudyIdInfo":{"id":"C3671023"},"secondaryIdInfos":[{"id":"NCT05842967","type":"REGISTRY","domain":"ClinicalTrials.gov"}],"organization":{"fullName":"Pfizer","class":"INDUSTRY"},"briefTitle":"A Study to Assess the Safety, Tolerability, and Immunogenicity of RSVpreF in Adults at High Risk of Severe RSV Disease","officialTitle":"A PHASE 3 PROTOCOL TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS (RSV) PREFUSION F SUBUNIT VACCINE IN ADULTS AT HIGH RISK OF SEVERE RSV DISEASE","acronym":"MONET"},"statusModule":{"statusVerifiedDate":"2025-07","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2023-05-11","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2024-03-18","type":"ACTUAL"},"completionDateStruct":{"date":"2024-03-18","type":"ACTUAL"},"studyFirstSubmitDate":"2023-04-24","studyFirstSubmitQcDate":"2023-04-24","studyFirstPostDateStruct":{"date":"2023-05-06","type":"ACTUAL"},"resultsFirstSubmitDate":"2025-03-03","resultsFirstSubmitQcDate":"2025-07-21","resultsFirstPostDateStruct":{"date":"2025-08-08","type":"ACTUAL"},"lastUpdateSubmitDate":"2025-07-21","lastUpdatePostDateStruct":{"date":"2025-08-08","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Pfizer","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"The purpose of this study is to learn about the safety and immunogenicity of a study vaccine (called RSVpreF) in several adult groups. Respiratory Syncytial Virus (RSV) is a common type of virus (germ) that can cause severe illness, where medical help is needed. RSV can lead to airway diseases in all ages. Vaccines help your body make antibodies which help fight against diseases. This is called an immune response. This study will measure how much antibody participants make after receiving RSVpreF (immunogenicity).\n\nThe study consists of 2 groups (Substudy A and Substudy B).\n\nSubstudy A is seeking approximately 675 participants who are:\n\n* Between 18 and 60 years of age.\n* Considered having a high likelihood of severe RSV disease due to certain long-term medical conditions. Such medical conditions do not include immunocompromising conditions.\n\nParticipants will need to come to the study clinic at least 2 times. At the first clinic visit, participants will receive 1 shot of RSVpreF or placebo in the arm by chance. A placebo looks like the study vaccine but contains no active ingredients. At each clinic visit, a blood sample will be taken. A third (final) visit can be either completed in clinic or via telephone contact. This study is about 6 months long for each participant.\n\nSubstudy B is seeking approximately 200 participants who are:\n\n* At least 18 years of age. About half of the participants will be at least 60 years of age.\n* Considered having a weakened immune system (immunocompromised). Participants will need to come to the study clinic at least 3 times. All participants will receive a shot of RSVpreF at the first study clinic visit. The second study clinic visit will be 1 month later. All participants will receive a second shot of the study vaccine at this second study clinic visit. Blood samples will be taken at the 3 study clinic visits. A fourth (final) visit can be either completed in clinic or via telephone contact. This study is about 7 months long for each participant.","detailedDescription":"This is a Phase 3 protocol that will assess the safety, tolerability, and immunogenicity of Pfizer's RSVpreF in adults at high risk of severe RSV disease. Each substudy design is detailed separately, and these substudies may be conducted in parallel, as required by the clinical plan, within the framework of this protocol.\n\nSubstudy A Design:\n\nThis is a Phase 3, multicenter, randomized, double-blinded, placebo-controlled study that will assess the safety, tolerability, and immunogenicity of Pfizer's RSVpreF in adults 18 to \\<60 years of age considered to be at high risk of RSV disease due to certain chronic medical conditions.\n\nApproximately 675 participants ≥18 to \\<60 years of age considered at high risk of RSV disease due to certain chronic medical conditions, excluding immunocompromising conditions, will be randomized to receive a single 120-µg dose of RSVpreF or placebo in a 2:1 ratio. Enrollment will be monitored to help ensure distribution of vaccination across the age range. The duration of study participation for each participant will be 6 months, with 3 scheduled visits.\n\nAll participants will have blood drawn at baseline prior to vaccination and at 1 month after vaccination to assess immunogenicity. Immunogenicity elicited at 1 month after vaccination with RSVpreF in Substudy A will be bridged to the immunogenicity of participants 60 years of age and older in the C3671013 study, in which RSVpreF efficacy was demonstrated.\n\nLocal reaction and systemic event data will be collected in an e-diary for 7 days after study vaccination (Days 1 through 7, where Day 1 is the day of vaccination). Reported Grade 3 reactogenicity will be assessed by the study site to determine if an unscheduled visit is required.\n\nFor all participants, AEs will be collected from informed consent through 1 month following study intervention administration, and AESIs, NDCMCs and SAEs will be collected from informed consent throughout study participation. In addition, AEs occurring up to 48 hours after blood draws that are related to study procedures will be collected.\n\nSubstudy B Design:\n\nThis is a Phase 3, single-arm, open-label, multicenter study that will assess the safety, tolerability, and immunogenicity of Pfizer's RSVpreF in immunocompromised adults.\n\nSubstudy B included approximately 200 immunocompromised adults ≥18 years of age, that will receive 2 120-µg doses of RSVpreF with an interval of 1 month. Approximately 100 participants will be ≥60 years of age and approximately 100 participants will be ≥18 to 60 years of age. Enrollment will be monitored to help ensure distribution of vaccination across the age ranges and underlying immunocompromising conditions. The duration of study participation for each participant will be 7 months, with 4 scheduled visits. All participants will have blood drawn at baseline prior to vaccination and at 1 month after (each) vaccination to assess immunogenicity.\n\nLocal reaction and systemic event data will be collected in an e-diary for 7 days after study vaccination (Days 1 through 7, where Day 1 is the day of vaccination). Reported Grade 3 reactogenicity will be assessed by the study site to determine if an unscheduled visit is required.\n\nFor all participants, AEs will be collected from informed consent through 1 month following the last study intervention administration, and AESIs, NDCMCs and SAEs will be collected from informed consent throughout study participation. In addition, AEs occurring up to 48 hours after blood draws that are related to study procedures will be collected."},"conditionsModule":{"conditions":["RESPIRATORY SYNCYTIAL VIRUS (RSV)"],"keywords":["RESPIRATORY SYNCYTIAL VIRUS (RSV)","ADULTS AT HIGH RISK","IMMUNOCOMPROMISED ADULTS"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","interventionModelDescription":"Substudy A: Phase 3, multicenter, randomized, double-blinded, placebo-controlled study that will assess the safety, tolerability, and immunogenicity of Pfizer's RSVpreF in adults 18 to \\<60 years of age considered to be at high risk of RSV disease due to certain chronic medical conditions. Approximately 675 participants ≥18 to \\<60 years of age considered at high risk of RSV disease due to certain chronic medical conditions, excluding immunocompromising conditions, will be randomized to receive a single 120-µg dose of RSVpreF or placebo in a 2:1 ratio.\n\nSubstudy B: Phase 3, single-arm, open-label, multicenter study that will assess the safety, tolerability, and immunogenicity of Pfizer's RSVpreF in immunocompromised adults. Approximately 200 immunocompromised adults ≥18 years of age will receive 2 120-µg doses of RSVpreF with an interval of 1 month. Approximately 100 participants will be ≥60 years of age and approximately 100 participants will be ≥18 to 60 years of age.","primaryPurpose":"PREVENTION","maskingInfo":{"masking":"TRIPLE","maskingDescription":"Substudy A is double blind therefore all parties (participant, site staff and sponsor) will be blinded to study intervention.\n\nSubstudy B is open-label therefore no blinding requirements are in place since all participants will receive RSVpreF.","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR"]}},"enrollmentInfo":{"count":885,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Substudy A - RSVpreF","type":"EXPERIMENTAL","description":"Participants will receive a single 120-µg dose of RSVpreF at Visit 1","interventionNames":["Biological: RSVpreF"]},{"label":"Substudy A - Placebo","type":"PLACEBO_COMPARATOR","description":"Participants will receive placebo at Visit 1","interventionNames":["Other: Placebo"]},{"label":"Substudy B - RSVpreF","type":"EXPERIMENTAL","description":"Participants will receive 120-µg doses of RSVpreF at Visit 1 and Visit 2 (open label, single arm only)","interventionNames":["Biological: RSVpreF"]}],"interventions":[{"type":"BIOLOGICAL","name":"RSVpreF","description":"120-µg","armGroupLabels":["Substudy A - RSVpreF","Substudy B - RSVpreF"]},{"type":"OTHER","name":"Placebo","description":"Placebo","armGroupLabels":["Substudy A - Placebo"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"SSA: Percentage of Participants With Local Reactions Within 7 Days After Vaccination","description":"Local reactions included pain at injection site, redness and swelling, recorded by participants in an electronic diary (e-diary). Pain at injection site was graded as mild: did not interfere with activity; moderate: interfered with activity and severe: prevented daily activity. Redness and swelling were measured and recorded in measuring device units, where 1 measuring device unit =0.5 centimeter (cm). Redness and swelling were graded as mild: \\>2.5 cm to 5.0 cm; moderate: \\>5.0 cm to 10.0 cm; severe: \\>10 cm.","timeFrame":"Within 7 Days after Vaccination (Vaccination on Day 1)"},{"measure":"SSA: Percentage of Participants With Systemic Events Within 7 Days After Vaccination","description":"Systemic events included fever, fatigue, headache, vomiting, nausea, diarrhea, muscle pain and joint pain. These were recorded by participants in an e-diary. Fever defined as oral temperature \\>=38.0 degrees Celsius (deg C) and categorized as mild: \\>=38.0 to 38.4 deg C, moderate: \\>38.4 to 38.9 deg C and severe: \\>38.9 to 40.0 deg C. Vomiting categorized as mild: 1-2 times in 24 hours (h); moderate: \\>2 times in 24h; severe: required intravenous (IV) hydration. Diarrhea categorized as mild: 2-3 loose stools in 24h; moderate: 4-5 loose stools in 24h; severe: 6 or more loose stools in 24h. Headache, fatigue, nausea, muscle pain and joint pain were categorized as mild: didn't interfere with activity; moderate: some interference with activity; severe: prevented daily routine activity.","timeFrame":"Within 7 Days after Vaccination (Vaccination on Day 1)"},{"measure":"SSA: Percentage of Participants With Adverse Events (AEs) From Vaccination Through 1 Month After Vaccination","description":"An AE was defined as any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were included. AEs included both serious and all non-serious adverse events.","timeFrame":"Within 1 Month after Vaccination (Vaccination on Day 1)"},{"measure":"SSA: Percentage of Participants With Newly Diagnosed Chronic Medical Conditions (NDCMCs) From Vaccination Throughout the Study","description":"A NDCMC was defined as a disease or medical condition that was not identified prior to study start and was expected to be persistent or otherwise long-lasting in its effects. Newly diagnosed chronic medical condition did not include illnesses considered to be temporary conditions.","timeFrame":"Within 6 Months after Vaccination (Vaccination on Day 1)"},{"measure":"SSA: Percentage of Participants With Serious Adverse Events (SAEs) Throughout the Study","description":"An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention. An SAE was defined as any untoward medical occurrence that, at any dose, met one or more of the following criteria - resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect and was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic and other important medical event were included in this outcome measure.","timeFrame":"Within 6 Months after Vaccination (Vaccination on Day 1)"},{"measure":"SSA: Geometric Mean Ratio (GMR) Estimated by Ratio of the Geometric Mean Titers (GMTs) at 1 Month After Vaccination in Study C3671023 Participants Compared to Study C3671013 Adults >= 60 Years","description":"In this outcome measure, GMTs for RSV A and RSV B neutralizing titers (NTs) are reported. In statistical section, GMT ratio estimated by the ratio of the GMTs for RSV A and RSV B serum NTs at 1 month after vaccination with RSVpreF in current study C3671023 participants to that in study C3671013 adults \\>=60 years of age, is reported. GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student t distribution).","timeFrame":"At 1 Month after Vaccination (Vaccination on Day 1)"},{"measure":"SSA: Percentage of Participants With Seroresponse Rate and Difference in Seroresponse Rates of RSV A and RSV B Serum NTs at 1 Month After Vaccination for Participants in Study C3671023 and C3671013 Adults >= 60 Years","description":"Seroresponse was defined as achieving a \\>=4-fold rise from baseline (before vaccination), if the baseline measurement was above the lower limit of quantitation (LLOQ). If the baseline measurement was below the LLOQ, a postvaccination assay result \\>=4\\* LLOQ was considered a seroresponse.","timeFrame":"At 1 Month after Vaccination (Vaccination on Day 1)"},{"measure":"SSB: Percentage of Participants With Local Reactions Within 7 Days After Vaccination 1","description":"Local reactions included pain at injection site, redness and swelling, recorded by participants in an e-diary. Pain at injection site was graded as mild: did not interfere with activity; moderate: interfered with activity and severe: prevented daily activity. Redness and swelling were measured and recorded in measuring device units, where 1 measuring device unit=0.5 cm. Redness and swelling were graded as mild: \\> 2.0 cm to 5.0 cm; moderate: \\> 5.0 cm to 10.0 cm and severe: \\> 10 cm.","timeFrame":"Within 7 Days after Vaccination 1 (Vaccination 1 on Day 1)"},{"measure":"SSB: Percentage of Participants With Local Reactions Within 7 Days After Vaccination 2","description":"Local reactions included pain at injection site, redness and swelling, recorded by participants in an e-diary. Pain at injection site was graded as mild: did not interfere with activity; moderate: interfered with activity and severe: prevented daily activity. Redness and swelling were measured and recorded in measuring device units, where 1 measuring device unit = 0.5 cm. Redness and swelling were graded as mild: \\>2.0 cm to 5.0 cm; moderate: \\>5.0 cm to 10.0 cm and severe: \\>10 cm.","timeFrame":"Within 7 Days after Vaccination 2 (Vaccination 2: 1-month post-vaccination 1 on Day 1)"},{"measure":"SSB: Percentage of Participants With Systemic Events Within 7 Days After Vaccination 1","description":"Systemic events included fever, fatigue, headache, vomiting, nausea, diarrhea, muscle pain and joint pain. These were recorded by participants in an e-diary. Fever defined as oral temperature \\>=38.0 degrees Celsius (deg C) and categorized as mild: \\>=38.0 to 38.4 deg C, moderate: \\>38.4 to 38.9 deg C and severe: \\>38.9 to 40.0 deg C. Vomiting categorized as mild: 1-2 times in 24 hours (h); moderate: \\>2 times in 24h; severe: required intravenous (IV) hydration. Diarrhea categorized as mild: 2-3 loose stools in 24h; moderate: 4-5 loose stools in 24h; severe: 6 or more loose stools in 24h. Headache, fatigue, nausea, muscle pain and joint pain were categorized as mild: didn't interfere with activity; moderate: some interference with activity; severe: prevented daily routine activity.","timeFrame":"Within 7 Days after Vaccination 1 (Vaccination 1 on Day 1)"},{"measure":"SSB: Percentage of Participants With Systemic Events Within 7 Days After Vaccination 2","description":"Systemic events included fever, fatigue, headache, vomiting, nausea, diarrhea, muscle pain and joint pain. These were recorded by participants in an e-diary. Fever defined as oral temperature \\>=38.0 degrees Celsius (deg C) and categorized as mild: \\>=38.0 to 38.4 deg C, moderate: \\>38.4 to 38.9 deg C and severe: \\>38.9 to 40.0 deg C. Vomiting categorized as mild: 1-2 times in 24 hours (h); moderate: \\>2 times in 24h; severe: required intravenous (IV) hydration. Diarrhea categorized as mild: 2-3 loose stools in 24h; moderate: 4-5 loose stools in 24h; severe: 6 or more loose stools in 24h. Headache, fatigue, nausea, muscle pain and joint pain were categorized as mild: didn't interfere with activity; moderate: some interference with activity; severe: prevented daily routine activity.","timeFrame":"Within 7 Days after Vaccination 2 (Vaccination 2: 1-month post-vaccination 1 on Day 1)"},{"measure":"SSB: Percentage of Participants With AEs From Vaccination 1 Through 1 Month After Vaccination 2","description":"An AE was defined as any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were included. AEs included both serious and all non-serious adverse events.","timeFrame":"From Vaccination 1 (on Day 1) through 1 month after Vaccination 2 (1 month after Vaccination 1) [approximately up to maximum of 2 months]"},{"measure":"SSB: Percentage of Participants With NDCMCs From Vaccination Throughout the Study","description":"A NDCMC was defined as a disease or medical condition that was not identified prior to study start and was expected to be persistent or otherwise long-lasting in its effects. Newly diagnosed chronic medical condition did not include illnesses considered to be temporary conditions.","timeFrame":"From Vaccination 1 (on Day 1) through 6 months after Vaccination 2 (1 month after Vaccination 1) [approximately up to maximum of 7 months]"},{"measure":"SSB: Percentage of Participants With SAEs Throughout the Study","description":"An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention. An SAE was defined as any untoward medical occurrence that, at any dose, met one or more of the following criteria - resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect and was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic and other important medical event were included in this outcome measure.","timeFrame":"From Vaccination 1 (on Day 1) through 6 months after Vaccination 2 (1 month after Vaccination 1) [approximately up to maximum of 7 months]"},{"measure":"SSB: GMT of NT for RSV A and RSV B Before Vaccination 1","description":"GMT of RSV A and RSV B before vaccination were reported in this outcome measure. Assay results below the lower limit of quantification (LLOQ) were set to 0.5\\*LLOQ. GMTs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution).","timeFrame":"Before Vaccination 1 (on Day 1)"},{"measure":"SSB: GMT of NT for RSV A and RSV B 1 Month After Vaccination 1","description":"GMT of RSV A and RSV B before vaccination were reported in this outcome measure. Assay results below the lower limit of quantification (LLOQ) were set to 0.5\\*LLOQ. GMTs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution).","timeFrame":"1 Month After Vaccination 1 (on Day 1)"},{"measure":"SSB: GMT of NT for RSV A and RSV B 1 Month After Vaccination 2","description":"GMT of RSV A and RSV B before vaccination were reported in this outcome measure. Assay results below the lower limit of quantification (LLOQ) were set to 0.5\\*LLOQ. GMTs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution).","timeFrame":"1 Month After Vaccination 2 (1-month post Vaccination 1)"}],"secondaryOutcomes":[{"measure":"SSB: Geometric Mean Fold Rise (GMFR) of NTs for RSV A and RSV B From Vaccination 1 to 1 Month Post-Vaccination 1","description":"GMFRs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution).","timeFrame":"At 1 Month After Vaccination 1 (on Day 1) to 1 Month Post-Vaccination 1"},{"measure":"SSB: GMFR of NTs for RSV A and RSV B From Vaccination 1 to 1 Month Post-Vaccination 2","description":"GMFRs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution).","timeFrame":"At 1 Month After Vaccination 1 (on Day 1) to 1 Month Post-Vaccination 2"},{"measure":"SSA: GMT of NTs for RSV A and RSV B Before Vaccination and 1 Month After Vaccination","description":"GMTs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution).","timeFrame":"SSA: Before Vaccination (on Day 1) and 1 Month After Vaccination"},{"measure":"SSA: GMFR of NTs for RSV A and RSV B From Before Vaccination to 1 Month After Vaccination","description":"GMFRs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution).","timeFrame":"SSA: Before Vaccination (on Day 1) and 1 Month After Vaccination"}]},"eligibilityModule":{"eligibilityCriteria":"Substudy A Inclusion Criteria:\n\n1. Capable of giving signed informed consent as described per protocol.\n2. Participants ≥18 to \\<60 years of age at study enrollment.\n3. Life expectancy ≥12 months (365 days) in the opinion of the investigator at enrollment.\n4. Participants who are willing and able to comply with all scheduled visits, vaccination plan, lifestyle considerations, and other study procedures.\n5. Participants who are considered at high risk of RSV disease by virtue of the following:\n\n   * Adults with chronic pulmonary (including asthma), cardiovascular (excluding isolated hypertension), renal, hepatic, neurologic, hematologic, or metabolic disorders (including diabetes mellitus).\n\nChronic medical conditions for this substudy are defined as:\n\n\\- Duration greater than 6 months.\n\n* Stable disease not requiring a significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of study intervention.\n* Requires regular medical follow-up or ongoing medication or hospitalization in the previous year.\n\n  • Additional groups at high risk include:\n* Residents of nursing homes and other long-term care facilities.\n\nSubstudy A Exclusion Criteria:\n\n1. Bleeding diathesis or condition associated with prolonged bleeding that would, in the opinion of the investigator, contraindicate intramuscular injection.\n2. History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis) to any component of the study intervention(s) or any related vaccine.\n3. Participants who do not have adequate deltoid muscle mass to allow intramuscular vaccination, in the opinion of the investigator.\n4. Serious chronic disorder, including metastatic malignancy, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the participant from participating in the study.\n5. Immunocompromised individuals with known or suspected immunodeficiency, as determined by history and/or laboratory/physical examination.\n6. Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.\n\n   Note: Specific criteria for participants with known stable infection with HIV can be found in protocol.\n7. Individuals who receive chronic systemic treatment with immunosuppressive therapy, including cytotoxic agents, immunosuppressive monoclonal antibodies, systemic corticosteroids\\*, eg, for cancer or an autoimmune disease, or radiotherapy, from 60 days before study intervention administration or planned receipt throughout the study.\n\n   \\*Applies to systemic corticosteroids administered for ≥14 days at a dose of ≥20 mg/day of prednisone or equivalent (eg, for cancer or an autoimmune disease). Systemic corticosteroids administered at a dose of \\<20 mg/day of prednisone or equivalent are permitted. Inhaled/nebulized, intra-articular, intrabursal, or topical (skin, eyes, or ears) corticosteroids are permitted.\n8. Receipt of blood/plasma products or immunoglobulin within 60 days before study intervention administration or planned receipt of these medications prior to the final blood draw.\n\n   Note: Monoclonal antibodies with targeted mechanisms of action used in the management of chronic illnesses (eg, migraine headaches, osteoporosis) are permitted, provided they do not meet exclusion criterion 7.\n9. Previous vaccination with any licensed or investigational RSV vaccine or planned receipt during study participation.\n10. Participation in other studies involving an investigational product within 28 days prior to consent and/or through and including the 6-month follow-up visit.\n11. Investigator site staff directly involved in the conduct of the study and their family members, site staff otherwise supervised by the investigator, and sponsor and sponsor delegate employees directly involved in the conduct of the study and their family members.\n\nSubstudy B Inclusion Criteria\n\n1. Capable of giving signed informed consent as described per protocol.\n2. Participants ≥18 years of age at study enrollment.\n3. Life expectancy ≥12 months (365 days) in the opinion of the investigator at enrollment.\n4. Participants who are willing and able to comply with all scheduled visits, vaccination plan, lifestyle considerations, and other study procedures.\n5. Participants who are immunocompromised by virtue of the following:\n\n   •Having known advanced NSCLC with at least 1 of the following:\n   * Has received initial or maintenance chemotherapy at least 2 weeks (14 days) before enrollment (or is treatment-naïve), and is not expected to receive chemotherapy within at least 2 weeks (14 days) after dose administration of initial vaccination or second vaccination; and/or\n   * Is receiving checkpoint inhibitor treatment (PD-1/PD-L1 inhibitor, CTLA-4 inhibitor) and has undergone at least 1 treatment cycle prior to enrollment; or\n   * Is receiving targeted drug therapy (EGFR, ALK, ROS1, BRAF, RET, MET, NTRK inhibitors) and has undergone at least 1 treatment cycle prior to enrollment.\n\n   OR - Is currently undergoing maintenance hemodialysis treatment secondary to end-stage renal disease . OR - Is on active immunomodulator therapy (eg, TNFα inhibitor, tofacitinib, or MTX) for an autoimmune inflammatory disorder (eg, inflammatory arthritis, such as rheumatoid arthritis, psoriatic arthritis, and juvenile idiopathic arthritis, or inflammatory bowel disease, such as ulcerative colitis or Crohn's disease) at a stable\\*dose.\n\n   \\*Stable dose is defined as receiving the same dose for at least 3 months (84 days) with no changes in the 28 days prior to enrollment. See protocol for details on stable dose for MTX.\n\n   OR - Is receiving an SOT (kidney, liver, lung, or heart) at least 3 months (84 days) prior to enrollment (Visit 201) and with no acute rejection episodes within 2 months (60 days) prior to enrollment (Visit 201).\n\n   Substudy B Exclusion Criteria:\n\n1.Bleeding diathesis or condition associated with prolonged bleeding that would, in the opinion of the investigator, contraindicate intramuscular injection.\n\n2.History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis) to any component of the study intervention(s) or any related vaccine.\n\n3.Participants with a history of transplant rejection, or PTLD, or participants who have had treatment for these conditions within 3 months (84 days) prior to study enrollment.\n\n4.Participants who do not have adequate deltoid muscle mass to allow intramuscular vaccination, in the opinion of the investigator.\n\n5.Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.\n\nNote: Specific criteria for participants with known stable infection with HIV can be found in protocol.\n\n6.Receipt of investigational or approved monoclonal antibodies against RSV within 6 months before study intervention administration.\n\n7.Receipt of blood/plasma products or immunoglobulin (IVIG, SCIG) within 60 days before study intervention administration or planned receipt of these medications prior to the final blood draw.\n\nNote: Please see the inclusion criteria in the protocol regarding criteria for targeted immunoglobulin therapies for underlying medical conditions.\n\nNote: Monoclonal antibodies with targeted mechanisms of action used in the management of chronic illnesses (eg, migraine headaches, osteoporosis) are permitted.\n\n8.Previous vaccination with any licensed or investigational RSV vaccine or planned receipt during study participation.\n\n9.Participation in other studies involving an investigational product within 28 days prior to consent and/or through and including the 6-month follow-up visit.\n\n10.Investigator site staff directly involved in the conduct of the study and their family members, site staff otherwise supervised by the investigator, and sponsor and sponsor delegate employees directly involved in the conduct of the study and their family members.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Pfizer CT.gov Call Center","affiliation":"Pfizer","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"North Alabama Research Center","city":"Athens","state":"Alabama","zip":"35611","country":"United States","geoPoint":{"lat":34.80243,"lon":-86.97219}},{"facility":"Central Research Associates","city":"Birmingham","state":"Alabama","zip":"35205","country":"United States","geoPoint":{"lat":33.52066,"lon":-86.80249}},{"facility":"Medical Affiliated Research Center","city":"Huntsville","state":"Alabama","zip":"35801","country":"United States","geoPoint":{"lat":34.7304,"lon":-86.58594}},{"facility":"Hope Research Institute","city":"Phoenix","state":"Arizona","zip":"85018","country":"United States","geoPoint":{"lat":33.44838,"lon":-112.07404}},{"facility":"The Pain Center of Arizona","city":"Phoenix","state":"Arizona","zip":"85018","country":"United States","geoPoint":{"lat":33.44838,"lon":-112.07404}},{"facility":"Hope Research Institute","city":"Tempe","state":"Arizona","zip":"85284","country":"United States","geoPoint":{"lat":33.41477,"lon":-111.90931}},{"facility":"Orange County Research Center","city":"Lake Forest","state":"California","zip":"92630","country":"United States","geoPoint":{"lat":33.64697,"lon":-117.68922}},{"facility":"Kaiser Permanente","city":"Los Angeles","state":"California","zip":"90027","country":"United States","geoPoint":{"lat":34.05223,"lon":-118.24368}},{"facility":"Diablo Clinical Research, Inc.","city":"Walnut Creek","state":"California","zip":"94598","country":"United States","geoPoint":{"lat":37.90631,"lon":-122.06496}},{"facility":"New England Research Associates, LLC","city":"Bridgeport","state":"Connecticut","zip":"06606","country":"United States","geoPoint":{"lat":41.17923,"lon":-73.18945}},{"facility":"GW Medical Faculty Associates","city":"Washington D.C.","state":"District of Columbia","zip":"20037","country":"United States","geoPoint":{"lat":38.89511,"lon":-77.03637}},{"facility":"GW Vaccine Research Unit","city":"Washington D.C.","state":"District of Columbia","zip":"20037","country":"United States","geoPoint":{"lat":38.89511,"lon":-77.03637}},{"facility":"Alliance for Multispecialty Research, LLC","city":"Coral Gables","state":"Florida","zip":"33134","country":"United States","geoPoint":{"lat":25.72149,"lon":-80.26838}},{"facility":"Proactive Clinical Research,LLC","city":"Fort Lauderdale","state":"Florida","zip":"33308","country":"United States","geoPoint":{"lat":26.12231,"lon":-80.14338}},{"facility":"Clinical Neuroscience Solutions - Orlando - South Delaney Avenue","city":"Orlando","state":"Florida","zip":"32806","country":"United States","geoPoint":{"lat":28.53834,"lon":-81.37924}},{"facility":"University of Iowa","city":"Iowa City","state":"Iowa","zip":"52242","country":"United States","geoPoint":{"lat":41.66113,"lon":-91.53017}},{"facility":"Alliance for Multispecialty Research, LLC","city":"Wichita","state":"Kansas","zip":"67207","country":"United States","geoPoint":{"lat":37.69224,"lon":-97.33754}},{"facility":"Institute of Human Virology (IHV)","city":"Baltimore","state":"Maryland","zip":"21201","country":"United States","geoPoint":{"lat":39.29038,"lon":-76.61219}},{"facility":"Jadestone Clinical Research","city":"Silver Spring","state":"Maryland","zip":"20904","country":"United States","geoPoint":{"lat":38.99067,"lon":-77.02609}},{"facility":"Bio-Kinetic Clinical Applications, LLC dba QPS-MO","city":"Springfield","state":"Missouri","zip":"65802","country":"United States","geoPoint":{"lat":37.21533,"lon":-93.29824}},{"facility":"Bio-Kinetic Clinical Applications LLC dba QPS-MO (Patient Screening Only)","city":"Springfield","state":"Missouri","zip":"65807","country":"United States","geoPoint":{"lat":37.21533,"lon":-93.29824}},{"facility":"Bozeman Health Deaconess Hospital","city":"Bozeman","state":"Montana","zip":"59715","country":"United States","geoPoint":{"lat":45.67965,"lon":-111.03856}},{"facility":"University of Nebraska Medical Center","city":"Omaha","state":"Nebraska","zip":"68105","country":"United States","geoPoint":{"lat":41.25626,"lon":-95.94043}},{"facility":"University Of Nebraska Medical Center","city":"Omaha","state":"Nebraska","zip":"68198","country":"United States","geoPoint":{"lat":41.25626,"lon":-95.94043}},{"facility":"NYU Langone Health","city":"New York","state":"New York","zip":"10016","country":"United States","geoPoint":{"lat":40.71427,"lon":-74.00597}},{"facility":"Columbia University Irving Medical Center","city":"New York","state":"New York","zip":"10032","country":"United States","geoPoint":{"lat":40.71427,"lon":-74.00597}},{"facility":"Rochester Clinical Research, LLC","city":"Rochester","state":"New York","zip":"14609","country":"United States","geoPoint":{"lat":43.15478,"lon":-77.61556}},{"facility":"Accellacare - Wilmington","city":"Wilmington","state":"North Carolina","zip":"28401","country":"United States","geoPoint":{"lat":34.23556,"lon":-77.94604}},{"facility":"University Hospitals Cleveland Medical Center","city":"Cleveland","state":"Ohio","zip":"44106","country":"United States","geoPoint":{"lat":41.4995,"lon":-81.69541}},{"facility":"Alliance for Multispecialty Research, LLC","city":"Knoxville","state":"Tennessee","zip":"37909","country":"United States","geoPoint":{"lat":35.96064,"lon":-83.92074}},{"facility":"Orion Clinical Research","city":"Austin","state":"Texas","zip":"78759","country":"United States","geoPoint":{"lat":30.26715,"lon":-97.74306}},{"facility":"AIM Trials, LLC","city":"Plano","state":"Texas","zip":"75093","country":"United States","geoPoint":{"lat":33.01984,"lon":-96.69889}},{"facility":"Epic Medical Research","city":"Red Oak","state":"Texas","zip":"75154","country":"United States","geoPoint":{"lat":32.51764,"lon":-96.80444}},{"facility":"Clinical Trials of Texas, LLC","city":"San Antonio","state":"Texas","zip":"78229","country":"United States","geoPoint":{"lat":29.42412,"lon":-98.49363}},{"facility":"Charlottesville Medical Research","city":"Charlottesville","state":"Virginia","zip":"22911","country":"United States","geoPoint":{"lat":38.02931,"lon":-78.47668}},{"facility":"Alliance for Multispecialty Research, LLC","city":"Norfolk","state":"Virginia","zip":"23502","country":"United States","geoPoint":{"lat":36.84681,"lon":-76.28522}}]},"referencesModule":{"references":[{"pmid":"40266222","type":"DERIVED","citation":"Almeida NC, Parameswaran L, DeHaan EN, Wyper H, Rahman F, Jiang Q, Li W, Patton M, Lino MM, Majid-Mahomed Z, Malkin E, Davis M, Towner WJ, Saharia K, Ilangovan K, Kalinina E, Cooper D, Swanson KA, Anderson AS, Gurtman A, Munjal I. Immunogenicity and Safety of the Bivalent Respiratory Syncytial Virus Prefusion F Subunit Vaccine in Immunocompromised or Renally Impaired Adults. Vaccines (Basel). 2025 Mar 19;13(3):328. doi: 10.3390/vaccines13030328."},{"pmid":"39523547","type":"DERIVED","citation":"Davis M, Towner W, DeHaan E, Jiang Q, Li W, Rahman F, Patton M, Wyper H, Lino MM, Sarwar UN, Majid-Mahomed Z, Mehta S, Howitt W, Cannon K, Kalinina E, Cooper D, Swanson KA, Anderson AS, Gurtman A, Munjal I; MONeT Study Team. Bivalent RSVpreF Vaccine in Adults 18 to <60 Years Old With High-Risk Conditions. Clin Infect Dis. 2025 Apr 30;80(4):911-920. doi: 10.1093/cid/ciae550."}],"seeAlsoLinks":[{"label":"To obtain contact information for a study center near you, click here.","url":"https://pmiform.com/clinical-trial-info-request?StudyID=C3671023"}]},"ipdSharingStatementModule":{"ipdSharing":"YES","description":"Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical\\_trials/trial\\_data\\_and\\_results/data\\_requests.","url":"https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests"}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"For immunogenicity analysis for SSA, as planned, data of participants \\>=60 years vaccinated with RSVpreF in C3671013 \\[NCT05035212\\] study is used for comparison. These participants were not enrolled in the present study C3671023 \\[NCT05842967\\], only the relevant historical data was used for comparison as per the objectives.","recruitmentDetails":"Substudy A (SSA) and substudy B (SSB) are reported differently. SSA was randomized; SSB was open-label single-arm. Enrollment number 885 derived from participants with IP assigned in SSA (681 randomized) and SSB (204). Since no randomization in SSB (single arm), tables of SSB present 217 participants as starting substudy (signed informed consent), out of which 203 vaccinated. In SSA: 678 vaccinated.","groups":[{"id":"FG000","title":"SSA: RSVpreF","description":"Participants aged \\>=18 to \\<60 years received respiratory syncytial virus stabilized prefusion F subunit vaccine (RSVpreF) 120 microgram (mcg) intramuscularly on Day 1 of SSA."},{"id":"FG001","title":"SSA: Placebo","description":"Participants aged \\>=18 to \\<60 years received placebo (lyophile matched to RSVpreF) intramuscularly on Day 1 of SSA."},{"id":"FG002","title":"SSB: RSVpreF, >= 18 to < 60 Years","description":"Participants aged \\>=18 to \\<60 years received RSVpreF 120 mcg intramuscularly first dose on Day 1 of SSB (Vaccination 1) and second dose on 1-month post-vaccination 1 (Vaccination 2)."},{"id":"FG003","title":"SSB: RSVpreF, >= 60 Years","description":"Participants aged \\>=60 years received RSVpreF 120 mcg intramuscularly first dose on Day 1 of SSB (Vaccination 1) and second dose on 1-month post-vaccination 1 (Vaccination 2)."}],"periods":[{"title":"Period 1: SSA","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"454"},{"groupId":"FG001","numSubjects":"227"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"}]},{"type":"Vaccinated","achievements":[{"groupId":"FG000","numSubjects":"453"},{"groupId":"FG001","numSubjects":"225"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"432"},{"groupId":"FG001","numSubjects":"218"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"22"},{"groupId":"FG001","numSubjects":"9"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"}]}],"dropWithdraws":[{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"}]},{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"16"},{"groupId":"FG001","numSubjects":"4"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"}]},{"type":"Physician Decision","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"}]},{"type":"Randomized but not vaccinated","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"}]}]},{"title":"Period 2: SSB","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"101"},{"groupId":"FG003","numSubjects":"116"}]},{"type":"Vaccinated","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"96"},{"groupId":"FG003","numSubjects":"107"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"89"},{"groupId":"FG003","numSubjects":"103"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"12"},{"groupId":"FG003","numSubjects":"13"}]}],"dropWithdraws":[{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"2"},{"groupId":"FG003","numSubjects":"0"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"4"},{"groupId":"FG003","numSubjects":"3"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"0"}]},{"type":"Enrolled but not vaccinated","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"5"},{"groupId":"FG003","numSubjects":"9"}]},{"type":"Protocol Violation","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"1"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"Safety population included all enrolled participants who received the study intervention.","groups":[{"id":"BG000","title":"SSA: RSVpreF","description":"Participants aged \\>=18 to \\<60 years received RSVpreF 120 mcg intramuscularly on Day 1 of SSA."},{"id":"BG001","title":"SSA: Placebo","description":"Participants aged \\>=18 to \\<60 years received placebo (lyophile matched to RSVpreF) intramuscularly on Day 1 of SSA."},{"id":"BG002","title":"SSB: RSVpreF, >= 18 to < 60 Years","description":"Participants aged \\>=18 to \\<60 years received RSVpreF 120 mcg intramuscularly first dose on Day 1 of SSB (Vaccination 1) and second dose on 1-month post-vaccination 1 (Vaccination 2)."},{"id":"BG003","title":"SSB: RSVpreF, >= 60 Years","description":"Participants aged \\>=60 years received RSVpreF 120 mcg intramuscularly first dose on Day 1 of SSB (Vaccination 1) and second dose on 1-month post-vaccination 1 (Vaccination 2)."},{"id":"BG004","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"453"},{"groupId":"BG001","value":"225"},{"groupId":"BG002","value":"96"},{"groupId":"BG003","value":"107"},{"groupId":"BG004","value":"881"}]}],"measures":[{"title":"Age, Customized","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"18 to <60 years","measurements":[{"groupId":"BG000","value":"453"},{"groupId":"BG001","value":"225"},{"groupId":"BG002","value":"96"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"774"}]},{"title":">=60 years","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"107"},{"groupId":"BG004","value":"107"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"260"},{"groupId":"BG001","value":"152"},{"groupId":"BG002","value":"56"},{"groupId":"BG003","value":"53"},{"groupId":"BG004","value":"521"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"193"},{"groupId":"BG001","value":"73"},{"groupId":"BG002","value":"40"},{"groupId":"BG003","value":"54"},{"groupId":"BG004","value":"360"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"102"},{"groupId":"BG001","value":"48"},{"groupId":"BG002","value":"8"},{"groupId":"BG003","value":"3"},{"groupId":"BG004","value":"161"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"348"},{"groupId":"BG001","value":"175"},{"groupId":"BG002","value":"88"},{"groupId":"BG003","value":"101"},{"groupId":"BG004","value":"712"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"3"},{"groupId":"BG004","value":"8"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"3"},{"groupId":"BG004","value":"5"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"24"},{"groupId":"BG001","value":"9"},{"groupId":"BG002","value":"6"},{"groupId":"BG003","value":"2"},{"groupId":"BG004","value":"41"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"4"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"106"},{"groupId":"BG001","value":"57"},{"groupId":"BG002","value":"25"},{"groupId":"BG003","value":"15"},{"groupId":"BG004","value":"203"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"312"},{"groupId":"BG001","value":"152"},{"groupId":"BG002","value":"63"},{"groupId":"BG003","value":"87"},{"groupId":"BG004","value":"614"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"4"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"10"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"SSA: Percentage of Participants With Local Reactions Within 7 Days After Vaccination","description":"Local reactions included pain at injection site, redness and swelling, recorded by participants in an electronic diary (e-diary). Pain at injection site was graded as mild: did not interfere with activity; moderate: interfered with activity and severe: prevented daily activity. Redness and swelling were measured and recorded in measuring device units, where 1 measuring device unit =0.5 centimeter (cm). Redness and swelling were graded as mild: \\>2.5 cm to 5.0 cm; moderate: \\>5.0 cm to 10.0 cm; severe: \\>10 cm.","populationDescription":"E-diary safety population included all participants who received the study intervention with at least 1 day of e-diary data transmitted.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of Participants","timeFrame":"Within 7 Days after Vaccination (Vaccination on Day 1)","groups":[{"id":"OG000","title":"SSA: RSVpreF","description":"Participants aged \\>=18 to \\<60 years received RSVpreF 120 mcg intramuscularly on Day 1 of SSA."},{"id":"OG001","title":"SSA: Placebo","description":"Participants aged \\>=18 to \\<60 years received placebo (lyophile matched to RSVpreF) intramuscularly on Day 1 of SSA."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"451"},{"groupId":"OG001","value":"225"}]}],"classes":[{"title":"Pain at injection site: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"29.7","lowerLimit":"25.5","upperLimit":"34.2"},{"groupId":"OG001","value":"10.2","lowerLimit":"6.6","upperLimit":"14.9"}]}]},{"title":"Pain at injection site: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"5.5","lowerLimit":"3.6","upperLimit":"8.1"},{"groupId":"OG001","value":"0.4","lowerLimit":"0.0","upperLimit":"2.5"}]}]},{"title":"Pain at injection site: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.8"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"1.6"}]}]},{"title":"Redness: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"3.8","lowerLimit":"2.2","upperLimit":"6.0"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"1.6"}]}]},{"title":"Redness: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"2.2","lowerLimit":"1.1","upperLimit":"4.0"},{"groupId":"OG001","value":"0.4","lowerLimit":"0.0","upperLimit":"2.5"}]}]},{"title":"Redness: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.8"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"1.6"}]}]},{"title":"Swelling: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"4.0","lowerLimit":"2.4","upperLimit":"6.2"},{"groupId":"OG001","value":"0.4","lowerLimit":"0.0","upperLimit":"2.5"}]}]},{"title":"Swelling: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"2.9","lowerLimit":"1.5","upperLimit":"4.9"},{"groupId":"OG001","value":"0.4","lowerLimit":"0.0","upperLimit":"2.5"}]}]},{"title":"Swelling: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0.2","lowerLimit":"0.0","upperLimit":"1.2"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"1.6"}]}]}]},{"type":"PRIMARY","title":"SSA: Percentage of Participants With Systemic Events Within 7 Days After Vaccination","description":"Systemic events included fever, fatigue, headache, vomiting, nausea, diarrhea, muscle pain and joint pain. These were recorded by participants in an e-diary. Fever defined as oral temperature \\>=38.0 degrees Celsius (deg C) and categorized as mild: \\>=38.0 to 38.4 deg C, moderate: \\>38.4 to 38.9 deg C and severe: \\>38.9 to 40.0 deg C. Vomiting categorized as mild: 1-2 times in 24 hours (h); moderate: \\>2 times in 24h; severe: required intravenous (IV) hydration. Diarrhea categorized as mild: 2-3 loose stools in 24h; moderate: 4-5 loose stools in 24h; severe: 6 or more loose stools in 24h. Headache, fatigue, nausea, muscle pain and joint pain were categorized as mild: didn't interfere with activity; moderate: some interference with activity; severe: prevented daily routine activity.","populationDescription":"E-diary safety population included all participants who received the study intervention with at least 1 day of e-diary data transmitted.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Within 7 Days after Vaccination (Vaccination on Day 1)","groups":[{"id":"OG000","title":"SSA: RSVpreF","description":"Participants aged \\>=18 to \\<60 years received RSVpreF 120 mcg intramuscularly on Day 1 of SSA."},{"id":"OG001","title":"SSA: Placebo","description":"Participants aged \\>=18 to \\<60 years received placebo (lyophile matched to RSVpreF) intramuscularly on Day 1 of SSA."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"451"},{"groupId":"OG001","value":"225"}]}],"classes":[{"title":"Fever: 38.0°C to 38.4°C","categories":[{"measurements":[{"groupId":"OG000","value":"0.4","lowerLimit":"0.1","upperLimit":"1.6"},{"groupId":"OG001","value":"0.4","lowerLimit":"0.0","upperLimit":"2.5"}]}]},{"title":"Fever: >38.4°C to 38.9°C","categories":[{"measurements":[{"groupId":"OG000","value":"1.1","lowerLimit":"0.4","upperLimit":"2.6"},{"groupId":"OG001","value":"0.9","lowerLimit":"0.1","upperLimit":"3.2"}]}]},{"title":"Fever: >38.9°C to 40.0°C","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.8"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"1.6"}]}]},{"title":"Fatigue: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"18.2","lowerLimit":"14.7","upperLimit":"22.1"},{"groupId":"OG001","value":"22.2","lowerLimit":"17.0","upperLimit":"28.2"}]}]},{"title":"Fatigue: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"18.2","lowerLimit":"14.7","upperLimit":"22.1"},{"groupId":"OG001","value":"15.6","lowerLimit":"11.1","upperLimit":"21.0"}]}]},{"title":"Fatigue: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0.9","lowerLimit":"0.2","upperLimit":"2.3"},{"groupId":"OG001","value":"0.4","lowerLimit":"0.0","upperLimit":"2.5"}]}]},{"title":"Headache: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"20.8","lowerLimit":"17.2","upperLimit":"24.9"},{"groupId":"OG001","value":"18.7","lowerLimit":"13.8","upperLimit":"24.4"}]}]},{"title":"Headache: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"7.3","lowerLimit":"5.1","upperLimit":"10.1"},{"groupId":"OG001","value":"11.6","lowerLimit":"7.7","upperLimit":"16.5"}]}]},{"title":"Headache: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0.2","lowerLimit":"0.0","upperLimit":"1.2"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"1.6"}]}]},{"title":"Muscle Pain: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"15.7","lowerLimit":"12.5","upperLimit":"19.4"},{"groupId":"OG001","value":"9.8","lowerLimit":"6.2","upperLimit":"14.4"}]}]},{"title":"Muscle Pain: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"8.6","lowerLimit":"6.2","upperLimit":"11.6"},{"groupId":"OG001","value":"6.2","lowerLimit":"3.4","upperLimit":"10.2"}]}]},{"title":"Muscle Pain: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.8"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"1.6"}]}]},{"title":"Joint Pain: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"7.1","lowerLimit":"4.9","upperLimit":"9.9"},{"groupId":"OG001","value":"4.0","lowerLimit":"1.8","upperLimit":"7.5"}]}]},{"title":"Joint Pain: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"5.1","lowerLimit":"3.3","upperLimit":"7.6"},{"groupId":"OG001","value":"6.2","lowerLimit":"3.4","upperLimit":"10.2"}]}]},{"title":"Joint Pain: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0.2","lowerLimit":"0.0","upperLimit":"1.2"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"1.6"}]}]},{"title":"Nausea: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"9.3","lowerLimit":"6.8","upperLimit":"12.4"},{"groupId":"OG001","value":"8.9","lowerLimit":"5.5","upperLimit":"13.4"}]}]},{"title":"Nausea: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"2.4","lowerLimit":"1.2","upperLimit":"4.3"},{"groupId":"OG001","value":"0.9","lowerLimit":"0.1","upperLimit":"3.2"}]}]},{"title":"Nausea: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.8"},{"groupId":"OG001","value":"0.4","lowerLimit":"0.0","upperLimit":"2.5"}]}]},{"title":"Vomiting: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"1.6","lowerLimit":"0.6","upperLimit":"3.2"},{"groupId":"OG001","value":"0.4","lowerLimit":"0.0","upperLimit":"2.5"}]}]},{"title":"Vomiting: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"0.4","lowerLimit":"0.1","upperLimit":"1.6"},{"groupId":"OG001","value":"0.9","lowerLimit":"0.1","upperLimit":"3.2"}]}]},{"title":"Vomiting: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.8"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"1.6"}]}]},{"title":"Diarrhea: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"11.1","lowerLimit":"8.3","upperLimit":"14.4"},{"groupId":"OG001","value":"12.4","lowerLimit":"8.4","upperLimit":"17.5"}]}]},{"title":"Diarrhea: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"3.1","lowerLimit":"1.7","upperLimit":"5.2"},{"groupId":"OG001","value":"3.6","lowerLimit":"1.5","upperLimit":"6.9"}]}]},{"title":"Diarrhea: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0.7","lowerLimit":"0.1","upperLimit":"1.9"},{"groupId":"OG001","value":"0.9","lowerLimit":"0.1","upperLimit":"3.2"}]}]}]},{"type":"PRIMARY","title":"SSA: Percentage of Participants With Adverse Events (AEs) From Vaccination Through 1 Month After Vaccination","description":"An AE was defined as any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were included. AEs included both serious and all non-serious adverse events.","populationDescription":"Safety population included all enrolled participants who received the study intervention.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Within 1 Month after Vaccination (Vaccination on Day 1)","groups":[{"id":"OG000","title":"SSA: RSVpreF","description":"Participants aged \\>=18 to \\<60 years received RSVpreF 120 mcg intramuscularly on Day 1 of SSA."},{"id":"OG001","title":"SSA: Placebo","description":"Participants aged \\>=18 to \\<60 years received placebo (lyophile matched to RSVpreF) intramuscularly on Day 1 of SSA."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"453"},{"groupId":"OG001","value":"225"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.1","lowerLimit":"4.9","upperLimit":"9.8"},{"groupId":"OG001","value":"7.6","lowerLimit":"4.5","upperLimit":"11.8"}]}]}]},{"type":"PRIMARY","title":"SSA: Percentage of Participants With Newly Diagnosed Chronic Medical Conditions (NDCMCs) From Vaccination Throughout the Study","description":"A NDCMC was defined as a disease or medical condition that was not identified prior to study start and was expected to be persistent or otherwise long-lasting in its effects. Newly diagnosed chronic medical condition did not include illnesses considered to be temporary conditions.","populationDescription":"Safety population included all enrolled participants who received the study intervention.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Within 6 Months after Vaccination (Vaccination on Day 1)","groups":[{"id":"OG000","title":"SSA: RSVpreF","description":"Participants aged \\>=18 to \\<60 years received RSVpreF 120 mcg intramuscularly on Day 1 of SSA."},{"id":"OG001","title":"SSA: Placebo","description":"Participants aged \\>=18 to \\<60 years received placebo (lyophile matched to RSVpreF) intramuscularly on Day 1 of SSA."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"453"},{"groupId":"OG001","value":"225"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.7","lowerLimit":"0.1","upperLimit":"1.9"},{"groupId":"OG001","value":"2.2","lowerLimit":"0.7","upperLimit":"5.1"}]}]}]},{"type":"PRIMARY","title":"SSA: Percentage of Participants With Serious Adverse Events (SAEs) Throughout the Study","description":"An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention. An SAE was defined as any untoward medical occurrence that, at any dose, met one or more of the following criteria - resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect and was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic and other important medical event were included in this outcome measure.","populationDescription":"Safety population included all enrolled participants who received the study intervention.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Within 6 Months after Vaccination (Vaccination on Day 1)","groups":[{"id":"OG000","title":"SSA: RSVpreF","description":"Participants aged \\>=18 to \\<60 years received RSVpreF 120 mcg intramuscularly on Day 1 of SSA."},{"id":"OG001","title":"SSA: Placebo","description":"Participants aged \\>=18 to \\<60 years received placebo (lyophile matched to RSVpreF) intramuscularly on Day 1 of SSA."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"453"},{"groupId":"OG001","value":"225"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.1","lowerLimit":"0.4","upperLimit":"2.6"},{"groupId":"OG001","value":"3.1","lowerLimit":"1.3","upperLimit":"6.3"}]}]}]},{"type":"PRIMARY","title":"SSA: Geometric Mean Ratio (GMR) Estimated by Ratio of the Geometric Mean Titers (GMTs) at 1 Month After Vaccination in Study C3671023 Participants Compared to Study C3671013 Adults >= 60 Years","description":"In this outcome measure, GMTs for RSV A and RSV B neutralizing titers (NTs) are reported. In statistical section, GMT ratio estimated by the ratio of the GMTs for RSV A and RSV B serum NTs at 1 month after vaccination with RSVpreF in current study C3671023 participants to that in study C3671013 adults \\>=60 years of age, is reported. GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student t distribution).","populationDescription":"C3671023: Evaluable immunogenicity population: participants eligible for SSA; received study interventions (RSVpreF or placebo) to which they were randomized; had 1-month postvaccination blood collection 27-42 days after vaccination; had at least 1 valid and determinate assay result 1 month after vaccination; had no major protocol violations from vaccination up to 1-month postvaccination blood draw. C3671013: Immunogenicity subset. \"Number Analyzed\" = participants evaluable for specified rows.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Titer","timeFrame":"At 1 Month after Vaccination (Vaccination on Day 1)","groups":[{"id":"OG000","title":"C3671023 SSA: RSVpreF","description":"Participants aged \\>=18 to \\<60 years received RSVpreF 120 mcg intramuscularly on Day 1 of SSA."},{"id":"OG001","title":"C3671013: RSVpreF, >=60 Years","description":"Participants aged \\>=60 years who were vaccinated with RSVpreF 120 mcg in C3671013 study are included. Only the relevant historical data from these participants is utilized, they are not enrolled in the present study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"437"},{"groupId":"OG001","value":"408"}]}],"classes":[{"title":"RSV A","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"435"},{"groupId":"OG001","value":"408"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"41097","lowerLimit":"37986.1","upperLimit":"44463.4"},{"groupId":"OG001","value":"26225","lowerLimit":"24143.1","upperLimit":"28485.7"}]}]},{"title":"RSV B","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"437"},{"groupId":"OG001","value":"408"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"37416","lowerLimit":"34277.9","upperLimit":"40842.0"},{"groupId":"OG001","value":"24680","lowerLimit":"22504.3","upperLimit":"27065.4"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"NON_INFERIORITY","nonInferiorityComment":"Noninferiority was declared if both the null hypothesis of GMR and the null hypothesis of difference in seroresponse rates were rejected for both RSV A and RSV B serum NTs, with a type I error (2-sided) of 5%.","paramType":"GMR","paramValue":"1.57","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.396","ciUpperLimit":"1.759","estimateComment":"GMRs (ratio of GMTs from C3671023 SSA to C3671013 immunogenicity subset), 2-sided CI were calculated by exponentiating difference in LS means, corresponding CIs based on regression model. Data reported here is for RSV A."},{"groupIds":["OG000","OG001"],"nonInferiorityType":"NON_INFERIORITY","nonInferiorityComment":"Noninferiority was declared if both the null hypothesis of GMR and the null hypothesis of difference in seroresponse rates were rejected for both RSV A and RSV B serum NTs, with a type I error (2-sided) of 5%.","paramType":"GMR","paramValue":"1.52","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.333","ciUpperLimit":"1.725","estimateComment":"GMRs (ratio of GMTs from C3671023 SSA to C3671013 immunogenicity subset), 2-sided CI were calculated by exponentiating difference in LS means, corresponding CIs based on regression model. Data reported here is for RSV B."}]},{"type":"PRIMARY","title":"SSA: Percentage of Participants With Seroresponse Rate and Difference in Seroresponse Rates of RSV A and RSV B Serum NTs at 1 Month After Vaccination for Participants in Study C3671023 and C3671013 Adults >= 60 Years","description":"Seroresponse was defined as achieving a \\>=4-fold rise from baseline (before vaccination), if the baseline measurement was above the lower limit of quantitation (LLOQ). If the baseline measurement was below the LLOQ, a postvaccination assay result \\>=4\\* LLOQ was considered a seroresponse.","populationDescription":"C3671023: Evaluable immunogenicity population: participants eligible for SSA; received study interventions (RSVpreF or placebo) to which they were randomized; had 1-month postvaccination blood collection 27-42 days after vaccination; had at least 1 valid and determinate assay result 1 month after vaccination; had no major protocol violations from vaccination up to 1-month postvaccination blood draw. C3671013: Immunogenicity subset. \"Number Analyzed\" = participants evaluable for specified rows.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"At 1 Month after Vaccination (Vaccination on Day 1)","groups":[{"id":"OG000","title":"C3671023 SSA: RSVpreF","description":"Participants aged \\>=18 to \\<60 years received RSVpreF 120 mcg intramuscularly on Day 1 of SSA."},{"id":"OG001","title":"C3671013: RSVpreF, >=60 Years","description":"Participants aged \\>=60 years who were vaccinated with RSVpreF 120 mcg in C3671013 study are included. Only the relevant historical data from these participants is utilized, they are not enrolled in the present study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"437"},{"groupId":"OG001","value":"408"}]}],"classes":[{"title":"RSV A","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"435"},{"groupId":"OG001","value":"408"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"93.1","lowerLimit":"90.3","upperLimit":"95.3"},{"groupId":"OG001","value":"88.0","lowerLimit":"84.4","upperLimit":"91.0"}]}]},{"title":"RSV B","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"437"},{"groupId":"OG001","value":"408"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"93.4","lowerLimit":"90.6","upperLimit":"95.5"},{"groupId":"OG001","value":"85.0","lowerLimit":"81.2","upperLimit":"88.4"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"NON_INFERIORITY","nonInferiorityComment":"Noninferiority was declared if both the null hypothesis of GMR and the null hypothesis of difference in seroresponse rates were rejected for both RSV A and RSV B serum NTs, with a type I error (2-sided) of 5%.","paramType":"Difference in percentage","paramValue":"5.1","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.2","ciUpperLimit":"9.2","estimateComment":"Difference (C3671023 SSA, compared to C3671013 immunogenicity subset) in proportions, expressed as a percentage; 95% CIs for percentage difference were calculated using exact method based on Miettinen and Nurminen. Data reported here is for RSV A."},{"groupIds":["OG000","OG001"],"nonInferiorityType":"NON_INFERIORITY","nonInferiorityComment":"Noninferiority was declared if both the null hypothesis of GMR and the null hypothesis of difference in seroresponse rates were rejected for both RSV A and RSV B serum NTs, with a type I error (2-sided) of 5%.","paramType":"Difference in percentage","paramValue":"8.3","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"4.2","ciUpperLimit":"12.6","estimateComment":"Difference (C3671023 SSA, compared to C3671013 immunogenicity subset) in proportions, expressed as a percentage; 95% CIs for percentage difference were calculated using exact method based on Miettinen and Nurminen. Data reported here is for RSV B."}]},{"type":"PRIMARY","title":"SSB: Percentage of Participants With Local Reactions Within 7 Days After Vaccination 1","description":"Local reactions included pain at injection site, redness and swelling, recorded by participants in an e-diary. Pain at injection site was graded as mild: did not interfere with activity; moderate: interfered with activity and severe: prevented daily activity. Redness and swelling were measured and recorded in measuring device units, where 1 measuring device unit=0.5 cm. Redness and swelling were graded as mild: \\> 2.0 cm to 5.0 cm; moderate: \\> 5.0 cm to 10.0 cm and severe: \\> 10 cm.","populationDescription":"E-diary safety population included all participants who received the first dose of RSVpreF and had at least 1 day of e-diary data transferred during the Dose 1 e-diary collection period.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Within 7 Days after Vaccination 1 (Vaccination 1 on Day 1)","groups":[{"id":"OG000","title":"SSB: RSVpreF, >= 18 to < 60 Years","description":"Participants aged \\>=18 to \\<60 years received RSVpreF 120 mcg intramuscularly first dose on Day 1 of SSB (Vaccination 1) and second dose on 1-month post-vaccination 1 (Vaccination 2)."},{"id":"OG001","title":"SSB: RSVpreF, >= 60 Years","description":"Participants aged \\>=60 years received RSVpreF 120 mcg intramuscularly first dose on Day 1 of SSB (Vaccination 1) and second dose on 1-month post-vaccination 1 (Vaccination 2)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"96"},{"groupId":"OG001","value":"107"}]}],"classes":[{"title":"Pain at injection site: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"25.0","lowerLimit":"16.7","upperLimit":"34.9"},{"groupId":"OG001","value":"16.8","lowerLimit":"10.3","upperLimit":"25.3"}]}]},{"title":"Pain at injection site: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"1.0","lowerLimit":"0.0","upperLimit":"5.7"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"3.4"}]}]},{"title":"Pain at injection site: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"3.8"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"3.4"}]}]},{"title":"Redness: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"5.2","lowerLimit":"1.7","upperLimit":"11.7"},{"groupId":"OG001","value":"1.9","lowerLimit":"0.2","upperLimit":"6.6"}]}]},{"title":"Redness: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"1.0","lowerLimit":"0.0","upperLimit":"5.7"},{"groupId":"OG001","value":"1.9","lowerLimit":"0.2","upperLimit":"6.6"}]}]},{"title":"Redness: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"3.8"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"3.4"}]}]},{"title":"Swelling: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"6.3","lowerLimit":"2.3","upperLimit":"13.1"},{"groupId":"OG001","value":"0.9","lowerLimit":"0.0","upperLimit":"5.1"}]}]},{"title":"Swelling: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"2.1","lowerLimit":"0.3","upperLimit":"7.3"},{"groupId":"OG001","value":"1.9","lowerLimit":"0.2","upperLimit":"6.6"}]}]},{"title":"Swelling: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"3.8"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"3.4"}]}]}]},{"type":"PRIMARY","title":"SSB: Percentage of Participants With Local Reactions Within 7 Days After Vaccination 2","description":"Local reactions included pain at injection site, redness and swelling, recorded by participants in an e-diary. Pain at injection site was graded as mild: did not interfere with activity; moderate: interfered with activity and severe: prevented daily activity. Redness and swelling were measured and recorded in measuring device units, where 1 measuring device unit = 0.5 cm. Redness and swelling were graded as mild: \\>2.0 cm to 5.0 cm; moderate: \\>5.0 cm to 10.0 cm and severe: \\>10 cm.","populationDescription":"E-diary safety population included all participants who received 2 doses of RSVpreF and had at least 1 day of e-diary data transferred during the Dose 2 e-diary collection period. Here, 'Overall Number of Participants Analyzed' (N)= participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Within 7 Days after Vaccination 2 (Vaccination 2: 1-month post-vaccination 1 on Day 1)","groups":[{"id":"OG000","title":"SSB: RSVpreF, >= 18 to < 60 Years","description":"Participants aged \\>=18 to \\<60 years received RSVpreF 120 mcg intramuscularly first dose on Day 1 of SSB (Vaccination 1) and second dose on 1-month post-vaccination 1 (Vaccination 2)."},{"id":"OG001","title":"SSB: RSVpreF, >= 60 Years","description":"Participants aged \\>=60 years received RSVpreF 120 mcg intramuscularly first dose on Day 1 of SSB (Vaccination 1) and second dose on 1-month post-vaccination 1 (Vaccination 2)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"94"},{"groupId":"OG001","value":"105"}]}],"classes":[{"title":"Pain at injection site: Mild","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"94"},{"groupId":"OG001","value":"105"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"42.6","lowerLimit":"32.4","upperLimit":"53.2"},{"groupId":"OG001","value":"29.5","lowerLimit":"21.0","upperLimit":"39.2"}]}]},{"title":"Pain at injection site: Moderate","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"94"},{"groupId":"OG001","value":"105"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.3","lowerLimit":"1.2","upperLimit":"10.5"},{"groupId":"OG001","value":"1.9","lowerLimit":"0.2","upperLimit":"6.7"}]}]},{"title":"Pain at injection site: Severe","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"94"},{"groupId":"OG001","value":"105"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"3.8"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"3.5"}]}]},{"title":"Redness: Mild","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"94"},{"groupId":"OG001","value":"105"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.1","lowerLimit":"0.3","upperLimit":"7.5"},{"groupId":"OG001","value":"1.9","lowerLimit":"0.2","upperLimit":"6.7"}]}]},{"title":"Redness: Moderate","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"94"},{"groupId":"OG001","value":"104"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"3.8"},{"groupId":"OG001","value":"1.9","lowerLimit":"0.2","upperLimit":"6.7"}]}]},{"title":"Redness: Severe","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"94"},{"groupId":"OG001","value":"104"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"3.8"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"3.5"}]}]},{"title":"Swelling: Mild","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"94"},{"groupId":"OG001","value":"105"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.1","lowerLimit":"0.3","upperLimit":"7.5"},{"groupId":"OG001","value":"3.8","lowerLimit":"1.0","upperLimit":"9.5"}]}]},{"title":"Swelling: Moderate","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"94"},{"groupId":"OG001","value":"105"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.1","lowerLimit":"0.0","upperLimit":"5.8"},{"groupId":"OG001","value":"5.7","lowerLimit":"2.1","upperLimit":"12.0"}]}]},{"title":"Swelling: Severe","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"94"},{"groupId":"OG001","value":"105"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"3.8"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"3.5"}]}]}]},{"type":"PRIMARY","title":"SSB: Percentage of Participants With Systemic Events Within 7 Days After Vaccination 1","description":"Systemic events included fever, fatigue, headache, vomiting, nausea, diarrhea, muscle pain and joint pain. These were recorded by participants in an e-diary. Fever defined as oral temperature \\>=38.0 degrees Celsius (deg C) and categorized as mild: \\>=38.0 to 38.4 deg C, moderate: \\>38.4 to 38.9 deg C and severe: \\>38.9 to 40.0 deg C. Vomiting categorized as mild: 1-2 times in 24 hours (h); moderate: \\>2 times in 24h; severe: required intravenous (IV) hydration. Diarrhea categorized as mild: 2-3 loose stools in 24h; moderate: 4-5 loose stools in 24h; severe: 6 or more loose stools in 24h. Headache, fatigue, nausea, muscle pain and joint pain were categorized as mild: didn't interfere with activity; moderate: some interference with activity; severe: prevented daily routine activity.","populationDescription":"E-diary safety population included all participants who received the first dose of RSVpreF and had at least 1 day of e-diary data transferred during the Dose 1 e-diary collection period.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"96% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Within 7 Days after Vaccination 1 (Vaccination 1 on Day 1)","groups":[{"id":"OG000","title":"SSB: RSVpreF, >= 18 to < 60 Years","description":"Participants aged \\>=18 to \\<60 years received RSVpreF 120 mcg intramuscularly first dose on Day 1 of SSB (Vaccination 1) and second dose on 1-month post-vaccination 1 (Vaccination 2)."},{"id":"OG001","title":"SSB: RSVpreF, >= 60 Years","description":"Participants aged \\>=60 years received RSVpreF 120 mcg intramuscularly first dose on Day 1 of SSB (Vaccination 1) and second dose on 1-month post-vaccination 1 (Vaccination 2)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"96"},{"groupId":"OG001","value":"107"}]}],"classes":[{"title":"Fever: 38.0°C to 38.4°C","categories":[{"measurements":[{"groupId":"OG000","value":"1.0","lowerLimit":"0.0","upperLimit":"5.7"},{"groupId":"OG001","value":"0.9","lowerLimit":"0.0","upperLimit":"5.1"}]}]},{"title":"Fever: >38.4°C to 38.9°C","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"3.8"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"3.4"}]}]},{"title":"Fever: >38.9°C to 40.0°C","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"3.8"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"3.4"}]}]},{"title":"Fatigue: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"20.8","lowerLimit":"13.2","upperLimit":"30.3"},{"groupId":"OG001","value":"19.6","lowerLimit":"12.6","upperLimit":"28.4"}]}]},{"title":"Fatigue: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"16.7","lowerLimit":"9.8","upperLimit":"25.6"},{"groupId":"OG001","value":"22.4","lowerLimit":"14.9","upperLimit":"31.5"}]}]},{"title":"Fatigue: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"2.1","lowerLimit":"0.3","upperLimit":"7.3"},{"groupId":"OG001","value":"2.8","lowerLimit":"0.6","upperLimit":"8.0"}]}]},{"title":"Headache: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"29.2","lowerLimit":"20.3","upperLimit":"39.3"},{"groupId":"OG001","value":"15.0","lowerLimit":"8.8","upperLimit":"23.1"}]}]},{"title":"Headache: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"9.4","lowerLimit":"4.4","upperLimit":"17.1"},{"groupId":"OG001","value":"6.5","lowerLimit":"2.7","upperLimit":"13.0"}]}]},{"title":"Headache: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"3.8"},{"groupId":"OG001","value":"0.9","lowerLimit":"0.0","upperLimit":"5.1"}]}]},{"title":"Vomiting: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"4.2","lowerLimit":"1.1","upperLimit":"10.3"},{"groupId":"OG001","value":"0.9","lowerLimit":"0.0","upperLimit":"5.1"}]}]},{"title":"Vomiting: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"3.8"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"3.4"}]}]},{"title":"Vomiting: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"3.8"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"3.4"}]}]},{"title":"Nausea: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"9.4","lowerLimit":"4.4","upperLimit":"17.1"},{"groupId":"OG001","value":"3.7","lowerLimit":"1.0","upperLimit":"9.3"}]}]},{"title":"Nausea: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"3.1","lowerLimit":"0.6","upperLimit":"8.9"},{"groupId":"OG001","value":"4.7","lowerLimit":"1.5","upperLimit":"10.6"}]}]},{"title":"Nausea: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"3.8"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"3.4"}]}]},{"title":"Diarrhea: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"15.6","lowerLimit":"9.0","upperLimit":"24.5"},{"groupId":"OG001","value":"12.1","lowerLimit":"6.6","upperLimit":"19.9"}]}]},{"title":"Diarrhea: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"6.3","lowerLimit":"2.3","upperLimit":"13.1"},{"groupId":"OG001","value":"5.6","lowerLimit":"2.1","upperLimit":"11.8"}]}]},{"title":"Diarrhea: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"3.8"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"3.4"}]}]},{"title":"Muscle Pain: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"18.8","lowerLimit":"11.5","upperLimit":"28.0"},{"groupId":"OG001","value":"13.1","lowerLimit":"7.3","upperLimit":"21.0"}]}]},{"title":"Muscle Pain: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"7.3","lowerLimit":"3.0","upperLimit":"14.4"},{"groupId":"OG001","value":"5.6","lowerLimit":"2.1","upperLimit":"11.8"}]}]},{"title":"Muscle Pain: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"3.8"},{"groupId":"OG001","value":"1.9","lowerLimit":"0.2","upperLimit":"6.6"}]}]},{"title":"Joint Pain: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"10.4","lowerLimit":"5.1","upperLimit":"18.3"},{"groupId":"OG001","value":"11.2","lowerLimit":"5.9","upperLimit":"18.8"}]}]},{"title":"Joint Pain: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"7.3","lowerLimit":"3.0","upperLimit":"14.4"},{"groupId":"OG001","value":"8.4","lowerLimit":"3.9","upperLimit":"15.4"}]}]},{"title":"Joint Pain: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"3.8"},{"groupId":"OG001","value":"1.9","lowerLimit":"0.2","upperLimit":"6.6"}]}]}]},{"type":"PRIMARY","title":"SSB: Percentage of Participants With Systemic Events Within 7 Days After Vaccination 2","description":"Systemic events included fever, fatigue, headache, vomiting, nausea, diarrhea, muscle pain and joint pain. These were recorded by participants in an e-diary. Fever defined as oral temperature \\>=38.0 degrees Celsius (deg C) and categorized as mild: \\>=38.0 to 38.4 deg C, moderate: \\>38.4 to 38.9 deg C and severe: \\>38.9 to 40.0 deg C. Vomiting categorized as mild: 1-2 times in 24 hours (h); moderate: \\>2 times in 24h; severe: required intravenous (IV) hydration. Diarrhea categorized as mild: 2-3 loose stools in 24h; moderate: 4-5 loose stools in 24h; severe: 6 or more loose stools in 24h. Headache, fatigue, nausea, muscle pain and joint pain were categorized as mild: didn't interfere with activity; moderate: some interference with activity; severe: prevented daily routine activity.","populationDescription":"E-diary safety population included all participants who received 2 doses of RSVpreF and had at least 1 day of e-diary data transferred during the Dose 2 e-diary collection period. Here, 'N'= participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Within 7 Days after Vaccination 2 (Vaccination 2: 1-month post-vaccination 1 on Day 1)","groups":[{"id":"OG000","title":"SSB: RSVpreF, >= 18 to < 60 Years","description":"Participants aged \\>=18 to \\<60 years received RSVpreF 120 mcg intramuscularly first dose on Day 1 of SSB (Vaccination 1) and second dose on 1-month post-vaccination 1 (Vaccination 2)."},{"id":"OG001","title":"SSB: RSVpreF, >= 60 Years","description":"Participants aged \\>=60 years received RSVpreF 120 mcg intramuscularly first dose on Day 1 of SSB (Vaccination 1) and second dose on 1-month post-vaccination 1 (Vaccination 2)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"94"},{"groupId":"OG001","value":"105"}]}],"classes":[{"title":"Fever: 38.0°C to 38.4°C","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"3.8"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"3.5"}]}]},{"title":"Fever: >38.4°C to 38.9°C","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"3.8"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"3.5"}]}]},{"title":"Fever: >38.9°C to 40.0°C","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"3.8"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"3.5"}]}]},{"title":"Fatigue: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"19.1","lowerLimit":"11.8","upperLimit":"28.6"},{"groupId":"OG001","value":"23.8","lowerLimit":"16.0","upperLimit":"33.1"}]}]},{"title":"Fatigue: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"18.1","lowerLimit":"10.9","upperLimit":"27.4"},{"groupId":"OG001","value":"19.0","lowerLimit":"12.0","upperLimit":"27.9"}]}]},{"title":"Fatigue: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"3.8"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"3.5"}]}]},{"title":"Headache: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"13.8","lowerLimit":"7.6","upperLimit":"22.5"},{"groupId":"OG001","value":"19.0","lowerLimit":"12.0","upperLimit":"27.9"}]}]},{"title":"Headache: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"10.6","lowerLimit":"5.2","upperLimit":"18.7"},{"groupId":"OG001","value":"5.7","lowerLimit":"2.1","upperLimit":"12.0"}]}]},{"title":"Headache: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"3.8"},{"groupId":"OG001","value":"1.0","lowerLimit":"0.0","upperLimit":"5.2"}]}]},{"title":"Vomiting: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"2.1","lowerLimit":"0.3","upperLimit":"7.5"},{"groupId":"OG001","value":"1.0","lowerLimit":"0.0","upperLimit":"5.2"}]}]},{"title":"Vomiting: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"3.8"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"3.5"}]}]},{"title":"Vomiting: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"3.8"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"3.5"}]}]},{"title":"Nausea: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"5.3","lowerLimit":"1.7","upperLimit":"12.0"},{"groupId":"OG001","value":"5.7","lowerLimit":"2.1","upperLimit":"12.0"}]}]},{"title":"Nausea: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"1.1","lowerLimit":"0.0","upperLimit":"5.8"},{"groupId":"OG001","value":"1.0","lowerLimit":"0.0","upperLimit":"5.2"}]}]},{"title":"Nausea: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"3.8"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"3.5"}]}]},{"title":"Diarrhea: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"6.4","lowerLimit":"2.4","upperLimit":"13.4"},{"groupId":"OG001","value":"10.5","lowerLimit":"5.3","upperLimit":"18.0"}]}]},{"title":"Diarrhea: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"5.3","lowerLimit":"1.7","upperLimit":"12.0"},{"groupId":"OG001","value":"2.9","lowerLimit":"0.6","upperLimit":"8.1"}]}]},{"title":"Diarrhea: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"3.8"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"3.5"}]}]},{"title":"Muscle Pain: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"16.0","lowerLimit":"9.2","upperLimit":"25.0"},{"groupId":"OG001","value":"15.2","lowerLimit":"9.0","upperLimit":"23.6"}]}]},{"title":"Muscle Pain: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"3.2","lowerLimit":"0.7","upperLimit":"9.0"},{"groupId":"OG001","value":"8.6","lowerLimit":"4.0","upperLimit":"15.6"}]}]},{"title":"Muscle Pain: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"3.8"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"3.5"}]}]},{"title":"Joint Pain: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"8.5","lowerLimit":"3.7","upperLimit":"16.1"},{"groupId":"OG001","value":"12.4","lowerLimit":"6.8","upperLimit":"20.2"}]}]},{"title":"Joint Pain: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"3.2","lowerLimit":"0.7","upperLimit":"9.0"},{"groupId":"OG001","value":"4.8","lowerLimit":"1.6","upperLimit":"10.8"}]}]},{"title":"Joint Pain: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"3.8"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"3.5"}]}]}]},{"type":"PRIMARY","title":"SSB: Percentage of Participants With AEs From Vaccination 1 Through 1 Month After Vaccination 2","description":"An AE was defined as any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were included. AEs included both serious and all non-serious adverse events.","populationDescription":"Safety population included all enrolled participants who received the study intervention.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"From Vaccination 1 (on Day 1) through 1 month after Vaccination 2 (1 month after Vaccination 1) [approximately up to maximum of 2 months]","groups":[{"id":"OG000","title":"SSB: RSVpreF, >= 18 to < 60 Years","description":"Participants aged \\>=18 to \\<60 years received RSVpreF 120 mcg intramuscularly first dose on Day 1 of SSB (Vaccination 1) and second dose on 1-month post-vaccination 1 (Vaccination 2)."},{"id":"OG001","title":"SSB: RSVpreF, >= 60 Years","description":"Participants aged \\>=60 years received RSVpreF 120 mcg intramuscularly first dose on Day 1 of SSB (Vaccination 1) and second dose on 1-month post-vaccination 1 (Vaccination 2)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"96"},{"groupId":"OG001","value":"107"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.5","lowerLimit":"7.4","upperLimit":"22.0"},{"groupId":"OG001","value":"22.4","lowerLimit":"14.9","upperLimit":"31.5"}]}]}]},{"type":"PRIMARY","title":"SSB: Percentage of Participants With NDCMCs From Vaccination Throughout the Study","description":"A NDCMC was defined as a disease or medical condition that was not identified prior to study start and was expected to be persistent or otherwise long-lasting in its effects. Newly diagnosed chronic medical condition did not include illnesses considered to be temporary conditions.","populationDescription":"Safety population included all enrolled participants who received the study intervention.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"From Vaccination 1 (on Day 1) through 6 months after Vaccination 2 (1 month after Vaccination 1) [approximately up to maximum of 7 months]","groups":[{"id":"OG000","title":"SSB: RSVpreF, >= 18 to < 60 Years","description":"Participants aged \\>=18 to \\<60 years received RSVpreF 120 mcg intramuscularly first dose on Day 1 of SSB (Vaccination 1) and second dose on 1-month post-vaccination 1 (Vaccination 2)."},{"id":"OG001","title":"SSB: RSVpreF, >= 60 Years","description":"Participants aged \\>=60 years received RSVpreF 120 mcg intramuscularly first dose on Day 1 of SSB (Vaccination 1) and second dose on 1-month post-vaccination 1 (Vaccination 2)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"96"},{"groupId":"OG001","value":"107"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.1","lowerLimit":"0.3","upperLimit":"7.3"},{"groupId":"OG001","value":"6.5","lowerLimit":"2.7","upperLimit":"13.0"}]}]}]},{"type":"PRIMARY","title":"SSB: Percentage of Participants With SAEs Throughout the Study","description":"An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention. An SAE was defined as any untoward medical occurrence that, at any dose, met one or more of the following criteria - resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect and was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic and other important medical event were included in this outcome measure.","populationDescription":"Safety population included all enrolled participants who received the study intervention.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"From Vaccination 1 (on Day 1) through 6 months after Vaccination 2 (1 month after Vaccination 1) [approximately up to maximum of 7 months]","groups":[{"id":"OG000","title":"SSB: RSVpreF, >= 18 to < 60 Years","description":"Participants aged \\>=18 to \\<60 years received RSVpreF 120 mcg intramuscularly first dose on Day 1 of SSB (Vaccination 1) and second dose on 1-month post-vaccination 1 (Vaccination 2)."},{"id":"OG001","title":"SSB: RSVpreF, >= 60 Years","description":"Participants aged \\>=60 years received RSVpreF 120 mcg intramuscularly first dose on Day 1 of SSB (Vaccination 1) and second dose on 1-month post-vaccination 1 (Vaccination 2)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"96"},{"groupId":"OG001","value":"107"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.3","lowerLimit":"3.0","upperLimit":"14.4"},{"groupId":"OG001","value":"14.0","lowerLimit":"8.1","upperLimit":"22.1"}]}]}]},{"type":"PRIMARY","title":"SSB: GMT of NT for RSV A and RSV B Before Vaccination 1","description":"GMT of RSV A and RSV B before vaccination were reported in this outcome measure. Assay results below the lower limit of quantification (LLOQ) were set to 0.5\\*LLOQ. GMTs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution).","populationDescription":"Evaluable immunogenicity population included all eligible participants for SSB who received 2 dose of RSVpreF; (blood collected for 1 month after last dose to be 27-42 days after second dose of RSVpreF; had at least 1 valid, determinate assay result 1 month after vaccination (1 month after second dose of RSVpreF); had no major protocol violations from vaccination through 1-month postvaccination blood draw (1 month after second dose of RSVpreF).","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Titer","timeFrame":"Before Vaccination 1 (on Day 1)","groups":[{"id":"OG000","title":"SSB: RSVpreF, >= 18 to < 60 Years","description":"Participants aged \\>=18 to \\<60 years received RSVpreF 120 mcg intramuscularly first dose on Day 1 of SSB (Vaccination 1) and second dose on 1-month post-vaccination 1 (Vaccination 2)."},{"id":"OG001","title":"SSB: RSVpreF, >= 60 Years","description":"Participants aged \\>=60 years received RSVpreF 120 mcg intramuscularly first dose on Day 1 of SSB (Vaccination 1) and second dose on 1-month post-vaccination 1 (Vaccination 2)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"90"},{"groupId":"OG001","value":"98"}]}],"classes":[{"title":"RSV A","categories":[{"measurements":[{"groupId":"OG000","value":"2943","lowerLimit":"2417.9","upperLimit":"3580.9"},{"groupId":"OG001","value":"3289","lowerLimit":"2735.1","upperLimit":"3954.1"}]}]},{"title":"RSV B","categories":[{"measurements":[{"groupId":"OG000","value":"2584","lowerLimit":"2120.6","upperLimit":"3147.9"},{"groupId":"OG001","value":"2992","lowerLimit":"2416.5","upperLimit":"3704.1"}]}]}]},{"type":"PRIMARY","title":"SSB: GMT of NT for RSV A and RSV B 1 Month After Vaccination 1","description":"GMT of RSV A and RSV B before vaccination were reported in this outcome measure. Assay results below the lower limit of quantification (LLOQ) were set to 0.5\\*LLOQ. GMTs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution).","populationDescription":"Evaluable immunogenicity population included all eligible participants for SSB who received 2 dose of RSVpreF; (blood collected for 1 month after last dose to be 27-42 days after second dose of RSVpreF; had at least 1 valid, determinate assay result 1 month after vaccination (1 month after second dose of RSVpreF); had no major protocol violations from vaccination through 1-month postvaccination blood draw (1 month after second dose of RSVpreF).","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Titer","timeFrame":"1 Month After Vaccination 1 (on Day 1)","groups":[{"id":"OG000","title":"SSB: RSVpreF, >= 18 to < 60 Years","description":"Participants aged \\>=18 to \\<60 years received RSVpreF 120 mcg intramuscularly first dose on Day 1 of SSB (Vaccination 1) and second dose on 1-month post-vaccination 1 (Vaccination 2)."},{"id":"OG001","title":"SSB: RSVpreF, >= 60 Years","description":"Participants aged \\>=60 years received RSVpreF 120 mcg intramuscularly first dose on Day 1 of SSB (Vaccination 1) and second dose on 1-month post-vaccination 1 (Vaccination 2)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"90"},{"groupId":"OG001","value":"98"}]}],"classes":[{"title":"RSV A","categories":[{"measurements":[{"groupId":"OG000","value":"26173","lowerLimit":"19937.1","upperLimit":"34359.2"},{"groupId":"OG001","value":"26075","lowerLimit":"20513.1","upperLimit":"33144.1"}]}]},{"title":"RSV B","categories":[{"measurements":[{"groupId":"OG000","value":"24701","lowerLimit":"18300.5","upperLimit":"33340.1"},{"groupId":"OG001","value":"25384","lowerLimit":"19749.5","upperLimit":"32626.2"}]}]}]},{"type":"PRIMARY","title":"SSB: GMT of NT for RSV A and RSV B 1 Month After Vaccination 2","description":"GMT of RSV A and RSV B before vaccination were reported in this outcome measure. Assay results below the lower limit of quantification (LLOQ) were set to 0.5\\*LLOQ. GMTs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution).","populationDescription":"Evaluable immunogenicity population included all eligible participants for SSB who received 2 dose of RSVpreF; (blood collected for 1 month after last dose to be 27-42 days after second dose of RSVpreF; had at least 1 valid, determinate assay result 1 month after vaccination (1 month after second dose of RSVpreF); had no major protocol violations from vaccination through 1-month postvaccination blood draw (1 month after second dose of RSVpreF).","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Titer","timeFrame":"1 Month After Vaccination 2 (1-month post Vaccination 1)","groups":[{"id":"OG000","title":"SSB: RSVpreF, >= 18 to < 60 Years","description":"Participants aged \\>=18 to \\<60 years received RSVpreF 120 mcg intramuscularly first dose on Day 1 of SSB (Vaccination 1) and second dose on 1-month post-vaccination 1 (Vaccination 2)."},{"id":"OG001","title":"SSB: RSVpreF, >= 60 Years","description":"Participants aged \\>=60 years received RSVpreF 120 mcg intramuscularly first dose on Day 1 of SSB (Vaccination 1) and second dose on 1-month post-vaccination 1 (Vaccination 2)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"90"},{"groupId":"OG001","value":"98"}]}],"classes":[{"title":"RSV A","categories":[{"measurements":[{"groupId":"OG000","value":"21910","lowerLimit":"17308.8","upperLimit":"27733.3"},{"groupId":"OG001","value":"25159","lowerLimit":"20085.1","upperLimit":"31515.2"}]}]},{"title":"RSV B","categories":[{"measurements":[{"groupId":"OG000","value":"20936","lowerLimit":"16154.0","upperLimit":"27134.4"},{"groupId":"OG001","value":"22774","lowerLimit":"18016.7","upperLimit":"28788.3"}]}]}]},{"type":"SECONDARY","title":"SSB: Geometric Mean Fold Rise (GMFR) of NTs for RSV A and RSV B From Vaccination 1 to 1 Month Post-Vaccination 1","description":"GMFRs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution).","populationDescription":"Evaluable immunogenicity population included all eligible participants for SSB who received 2 dose of RSVpreF; (blood collected for 1 month after last dose to be 27-42 days after second dose of RSVpreF; had at least 1 valid, determinate assay result 1 month after vaccination (1 month after second dose of RSVpreF); had no major protocol violations from vaccination through 1-month postvaccination blood draw (1 month after second dose of RSVpreF).","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Fold rise","timeFrame":"At 1 Month After Vaccination 1 (on Day 1) to 1 Month Post-Vaccination 1","groups":[{"id":"OG000","title":"SSB: RSVpreF, >= 18 to < 60 Years","description":"Participants aged \\>=18 to \\<60 years received RSVpreF 120 mcg intramuscularly first dose on Day 1 of SSB (Vaccination 1) and second dose on 1-month post-vaccination 1 (Vaccination 2)."},{"id":"OG001","title":"SSB: RSVpreF, >= 60 Years","description":"Participants aged \\>=60 years received RSVpreF 120 mcg intramuscularly first dose on Day 1 of SSB (Vaccination 1) and second dose on 1-month post-vaccination 1 (Vaccination 2)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"90"},{"groupId":"OG001","value":"98"}]}],"classes":[{"title":"RSV A","categories":[{"measurements":[{"groupId":"OG000","value":"8.8","lowerLimit":"6.76","upperLimit":"11.53"},{"groupId":"OG001","value":"7.9","lowerLimit":"6.21","upperLimit":"10.13"}]}]},{"title":"RSV B","categories":[{"measurements":[{"groupId":"OG000","value":"9.6","lowerLimit":"7.31","upperLimit":"12.51"},{"groupId":"OG001","value":"8.5","lowerLimit":"6.70","upperLimit":"10.75"}]}]}]},{"type":"SECONDARY","title":"SSB: GMFR of NTs for RSV A and RSV B From Vaccination 1 to 1 Month Post-Vaccination 2","description":"GMFRs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution).","populationDescription":"Evaluable immunogenicity population was analyzed.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Fold rise","timeFrame":"At 1 Month After Vaccination 1 (on Day 1) to 1 Month Post-Vaccination 2","groups":[{"id":"OG000","title":"SSB: RSVpreF, >= 18 to < 60 Years","description":"Participants aged \\>=18 to \\<60 years received RSVpreF 120 mcg intramuscularly first dose on Day 1 of SSB (Vaccination 1) and second dose on 1-month post-vaccination 1 (Vaccination 2)."},{"id":"OG001","title":"SSB: RSVpreF, >= 60 Years","description":"Participants aged \\>=60 years received RSVpreF 120 mcg intramuscularly first dose on Day 1 of SSB (Vaccination 1) and second dose on 1-month post-vaccination 1 (Vaccination 2)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"90"},{"groupId":"OG001","value":"98"}]}],"classes":[{"title":"RSV A","categories":[{"measurements":[{"groupId":"OG000","value":"7.4","lowerLimit":"5.88","upperLimit":"9.29"},{"groupId":"OG001","value":"7.7","lowerLimit":"6.11","upperLimit":"9.58"}]}]},{"title":"RSV B","categories":[{"measurements":[{"groupId":"OG000","value":"8.1","lowerLimit":"6.45","upperLimit":"10.18"},{"groupId":"OG001","value":"7.6","lowerLimit":"6.06","upperLimit":"9.57"}]}]}]},{"type":"SECONDARY","title":"SSA: GMT of NTs for RSV A and RSV B Before Vaccination and 1 Month After Vaccination","description":"GMTs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution).","populationDescription":"Evaluable immunogenicity population=participants who met following criteria:(i)eligible for Substudy A;(ii)received study interventions (RSVpreF or placebo)to which they were randomized;(iii)had 1-month postvaccination blood collected 27-42days after vaccination;(iv) had at least 1 valid,determinate assay result 1month after vaccination;(v)had no major protocol violations from vaccination through 1-month postvaccination blood draw. Here,'Number Analyzed'=participants evaluable at specified rows.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Titer","timeFrame":"SSA: Before Vaccination (on Day 1) and 1 Month After Vaccination","groups":[{"id":"OG000","title":"SSA: RSVpreF","description":"Participants aged \\>=18 to \\<60 years received RSVpreF 120 mcg intramuscularly on Day 1 of SSA."},{"id":"OG001","title":"SSA: Placebo","description":"Participants aged \\>=18 to \\<60 years received placebo (lyophile matched to RSVpreF) intramuscularly on Day 1 of SSA."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"437"},{"groupId":"OG001","value":"217"}]}],"classes":[{"title":"RSV A: Before Vaccination","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"436"},{"groupId":"OG001","value":"217"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2388","lowerLimit":"2207.7","upperLimit":"2583.3"},{"groupId":"OG001","value":"2797","lowerLimit":"2516.8","upperLimit":"3108.9"}]}]},{"title":"RSV A: 1 month after vaccination","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"436"},{"groupId":"OG001","value":"217"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"41595","lowerLimit":"38416.6","upperLimit":"45037.5"},{"groupId":"OG001","value":"2660","lowerLimit":"2395.2","upperLimit":"2953.9"}]}]},{"title":"RSV B: Before Vaccination","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"437"},{"groupId":"OG001","value":"217"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2075","lowerLimit":"1899.7","upperLimit":"2265.4"},{"groupId":"OG001","value":"2230","lowerLimit":"1988.6","upperLimit":"2501.6"}]}]},{"title":"RSV B: 1 month after vaccination","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"437"},{"groupId":"OG001","value":"217"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"38450","lowerLimit":"35187.5","upperLimit":"42014.7"},{"groupId":"OG001","value":"2135","lowerLimit":"1905.9","upperLimit":"2391.3"}]}]}]},{"type":"SECONDARY","title":"SSA: GMFR of NTs for RSV A and RSV B From Before Vaccination to 1 Month After Vaccination","description":"GMFRs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution).","populationDescription":"Evaluable immunogenicity population=participants who met following criteria:(i)eligible for Substudy A;(ii)received study interventions (RSVpreF or placebo)to which they were randomized;(iii)had 1-month postvaccination blood collected 27-42days after vaccination;(iv) had at least 1 valid,determinate assay result 1month after vaccination;(v)had no major protocol violations from vaccination through 1-month postvaccination blood draw. Here,'Number Analyzed'=participants evaluable at specified rows.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Fold rise","timeFrame":"SSA: Before Vaccination (on Day 1) and 1 Month After Vaccination","groups":[{"id":"OG000","title":"SSA: RSVpreF","description":"Participants aged \\>=18 to \\<60 years received RSVpreF 120 mcg intramuscularly on Day 1 of SSA."},{"id":"OG001","title":"SSA: Placebo","description":"Participants aged \\>=18 to \\<60 years received placebo (lyophile matched to RSVpreF) intramuscularly on Day 1 of SSA."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"437"},{"groupId":"OG001","value":"217"}]}],"classes":[{"title":"RSV A","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"435"},{"groupId":"OG001","value":"217"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"17.5","lowerLimit":"15.88","upperLimit":"19.21"},{"groupId":"OG001","value":"1.0","lowerLimit":"0.90","upperLimit":"1.00"}]}]},{"title":"RSV B","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"437"},{"groupId":"OG001","value":"217"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"18.5","lowerLimit":"16.76","upperLimit":"20.43"},{"groupId":"OG001","value":"1.0","lowerLimit":"0.91","upperLimit":"1.01"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"0","timeFrame":"SSA- LR/SE: Within 7Days after Vaccination (Vacc on Day1);AEs: Within 1 Month (M) after Vacc (Vacc on Day1), including any events reported up to 6 months; SAEs: Any events reported up to 6 months; SSB- LR/SE: Within 7 Days after Vacc1 (Day1 of SSB) Within 7 Days after Vacc 2 (second dose on 1M post-vacc.1); AEs: From Vacc 1 (on Day1) through 1M after Vacc 2 (1M after Vacc1) [approximately up to maximum of 2M], including any events reported up to 7 months; SAEs: any events reported up to 7 months","description":"Same event may appear as both SAE and non-SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another participant, or one participant may have experienced both a serious and non-serious event during the study. Safety population included all enrolled participants who received the study intervention.","eventGroups":[{"id":"EG000","title":"SSA: RSVpreF","description":"Participants aged \\>=18 to \\<60 years received RSVpreF 120 mcg intramuscularly on Day 1 of SSA.","deathsNumAffected":1,"deathsNumAtRisk":453,"seriousNumAffected":5,"seriousNumAtRisk":453,"otherNumAffected":301,"otherNumAtRisk":453},{"id":"EG001","title":"SSA: Placebo","description":"Participants aged \\>=18 to \\<60 years received placebo (lyophile matched to RSVpreF) intramuscularly on Day 1 of SSA.","deathsNumAffected":0,"deathsNumAtRisk":225,"seriousNumAffected":7,"seriousNumAtRisk":225,"otherNumAffected":135,"otherNumAtRisk":225},{"id":"EG002","title":"SSB: RSVpreF, >= 18 to < 60 Years","description":"Participants aged \\>=18 to \\<60 years received RSVpreF 120 mcg intramuscularly first dose on Day 1 of SSB (Vaccination 1) and second dose on 1-month post-vaccination 1 (Vaccination 2).","deathsNumAffected":0,"deathsNumAtRisk":96,"seriousNumAffected":7,"seriousNumAtRisk":96,"otherNumAffected":73,"otherNumAtRisk":96},{"id":"EG003","title":"SSB: RSVpreF, >= 60 Years","description":"Participants aged \\>=60 years received RSVpreF 120 mcg intramuscularly first dose on Day 1 of SSB (Vaccination 1) and second dose on 1-month post-vaccination 1 (Vaccination 2).","deathsNumAffected":0,"deathsNumAtRisk":107,"seriousNumAffected":15,"seriousNumAtRisk":107,"otherNumAffected":92,"otherNumAtRisk":107}],"seriousEvents":[{"term":"Cardio-respiratory arrest","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":453},{"groupId":"EG001","numAffected":0,"numAtRisk":225},{"groupId":"EG002","numAffected":0,"numAtRisk":96},{"groupId":"EG003","numAffected":0,"numAtRisk":107}]},{"term":"Tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":453},{"groupId":"EG001","numAffected":0,"numAtRisk":225},{"groupId":"EG002","numAffected":0,"numAtRisk":96},{"groupId":"EG003","numAffected":0,"numAtRisk":107}]},{"term":"Vertigo","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":453},{"groupId":"EG001","numAffected":0,"numAtRisk":225},{"groupId":"EG002","numAffected":0,"numAtRisk":96},{"groupId":"EG003","numAffected":0,"numAtRisk":107}]},{"term":"Non-cardiac chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":453},{"groupId":"EG001","numAffected":1,"numAtRisk":225},{"groupId":"EG002","numAffected":0,"numAtRisk":96},{"groupId":"EG003","numAffected":0,"numAtRisk":107}]},{"term":"Cholelithiasis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":453},{"groupId":"EG001","numAffected":1,"numAtRisk":225},{"groupId":"EG002","numAffected":0,"numAtRisk":96},{"groupId":"EG003","numAffected":0,"numAtRisk":107}]},{"term":"Appendicitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":453},{"groupId":"EG001","numAffected":1,"numAtRisk":225},{"groupId":"EG002","numAffected":0,"numAtRisk":96},{"groupId":"EG003","numAffected":0,"numAtRisk":107}]},{"term":"Postoperative wound infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":453},{"groupId":"EG001","numAffected":0,"numAtRisk":225},{"groupId":"EG002","numAffected":0,"numAtRisk":96},{"groupId":"EG003","numAffected":0,"numAtRisk":107}]},{"term":"Ankle fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":453},{"groupId":"EG001","numAffected":1,"numAtRisk":225},{"groupId":"EG002","numAffected":0,"numAtRisk":96},{"groupId":"EG003","numAffected":0,"numAtRisk":107}]},{"term":"Malignant glioma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":453},{"groupId":"EG001","numAffected":1,"numAtRisk":225},{"groupId":"EG002","numAffected":0,"numAtRisk":96},{"groupId":"EG003","numAffected":0,"numAtRisk":107}]},{"term":"Paraesthesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":453},{"groupId":"EG001","numAffected":0,"numAtRisk":225},{"groupId":"EG002","numAffected":0,"numAtRisk":96},{"groupId":"EG003","numAffected":0,"numAtRisk":107}]},{"term":"Depression","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":453},{"groupId":"EG001","numAffected":1,"numAtRisk":225},{"groupId":"EG002","numAffected":0,"numAtRisk":96},{"groupId":"EG003","numAffected":0,"numAtRisk":107}]},{"term":"Schizophrenia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":453},{"groupId":"EG001","numAffected":1,"numAtRisk":225},{"groupId":"EG002","numAffected":0,"numAtRisk":96},{"groupId":"EG003","numAffected":0,"numAtRisk":107}]},{"term":"Suicidal ideation","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":453},{"groupId":"EG001","numAffected":0,"numAtRisk":225},{"groupId":"EG002","numAffected":0,"numAtRisk":96},{"groupId":"EG003","numAffected":0,"numAtRisk":107}]},{"term":"Acute respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":453},{"groupId":"EG001","numAffected":1,"numAtRisk":225},{"groupId":"EG002","numAffected":0,"numAtRisk":96},{"groupId":"EG003","numAffected":1,"numAtRisk":107}]},{"term":"Chronic obstructive pulmonary disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":453},{"groupId":"EG001","numAffected":1,"numAtRisk":225},{"groupId":"EG002","numAffected":0,"numAtRisk":96},{"groupId":"EG003","numAffected":0,"numAtRisk":107}]},{"term":"Acute myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA v27.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":453},{"groupId":"EG001","numAffected":0,"numAtRisk":225},{"groupId":"EG002","numAffected":0,"numAtRisk":96},{"groupId":"EG003","numAffected":1,"numAtRisk":107}]},{"term":"Vertigo positional","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA v27.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":453},{"groupId":"EG001","numAffected":0,"numAtRisk":225},{"groupId":"EG002","numAffected":0,"numAtRisk":96},{"groupId":"EG003","numAffected":1,"numAtRisk":107}]},{"term":"Visual impairment","organSystem":"Eye disorders","sourceVocabulary":"MedDRA v27.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":453},{"groupId":"EG001","numAffected":0,"numAtRisk":225},{"groupId":"EG002","numAffected":0,"numAtRisk":96},{"groupId":"EG003","numAffected":1,"numAtRisk":107}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v27.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":453},{"groupId":"EG001","numAffected":0,"numAtRisk":225},{"groupId":"EG002","numAffected":0,"numAtRisk":96},{"groupId":"EG003","numAffected":1,"numAtRisk":107}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA v27.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":453},{"groupId":"EG001","numAffected":0,"numAtRisk":225},{"groupId":"EG002","numAffected":1,"numAtRisk":96},{"groupId":"EG003","numAffected":0,"numAtRisk":107}]},{"term":"Kidney transplant rejection","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA v27.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":453},{"groupId":"EG001","numAffected":0,"numAtRisk":225},{"groupId":"EG002","numAffected":1,"numAtRisk":96},{"groupId":"EG003","numAffected":0,"numAtRisk":107}]},{"term":"Transplant rejection","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA v27.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":453},{"groupId":"EG001","numAffected":0,"numAtRisk":225},{"groupId":"EG002","numAffected":0,"numAtRisk":96},{"groupId":"EG003","numAffected":1,"numAtRisk":107}]},{"term":"Bronchopulmonary aspergillosis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v27.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":453},{"groupId":"EG001","numAffected":0,"numAtRisk":225},{"groupId":"EG002","numAffected":0,"numAtRisk":96},{"groupId":"EG003","numAffected":1,"numAtRisk":107}]},{"term":"COVID-19","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v27.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":453},{"groupId":"EG001","numAffected":0,"numAtRisk":225},{"groupId":"EG002","numAffected":1,"numAtRisk":96},{"groupId":"EG003","numAffected":0,"numAtRisk":107}]},{"term":"COVID-19 pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v27.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":453},{"groupId":"EG001","numAffected":0,"numAtRisk":225},{"groupId":"EG002","numAffected":0,"numAtRisk":96},{"groupId":"EG003","numAffected":1,"numAtRisk":107}]},{"term":"Cellulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v27.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":453},{"groupId":"EG001","numAffected":0,"numAtRisk":225},{"groupId":"EG002","numAffected":0,"numAtRisk":96},{"groupId":"EG003","numAffected":1,"numAtRisk":107}]},{"term":"Cystitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v27.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":453},{"groupId":"EG001","numAffected":0,"numAtRisk":225},{"groupId":"EG002","numAffected":1,"numAtRisk":96},{"groupId":"EG003","numAffected":0,"numAtRisk":107}]},{"term":"Endocarditis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v27.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":453},{"groupId":"EG001","numAffected":0,"numAtRisk":225},{"groupId":"EG002","numAffected":0,"numAtRisk":96},{"groupId":"EG003","numAffected":1,"numAtRisk":107}]},{"term":"Enterococcal sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v27.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":453},{"groupId":"EG001","numAffected":0,"numAtRisk":225},{"groupId":"EG002","numAffected":0,"numAtRisk":96},{"groupId":"EG003","numAffected":1,"numAtRisk":107}]},{"term":"Osteomyelitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v27.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":453},{"groupId":"EG001","numAffected":0,"numAtRisk":225},{"groupId":"EG002","numAffected":0,"numAtRisk":96},{"groupId":"EG003","numAffected":1,"numAtRisk":107}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v27.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":453},{"groupId":"EG001","numAffected":0,"numAtRisk":225},{"groupId":"EG002","numAffected":1,"numAtRisk":96},{"groupId":"EG003","numAffected":0,"numAtRisk":107}]},{"term":"SARS-CoV-2 sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v27.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":453},{"groupId":"EG001","numAffected":0,"numAtRisk":225},{"groupId":"EG002","numAffected":0,"numAtRisk":96},{"groupId":"EG003","numAffected":1,"numAtRisk":107}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v27.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":453},{"groupId":"EG001","numAffected":0,"numAtRisk":225},{"groupId":"EG002","numAffected":0,"numAtRisk":96},{"groupId":"EG003","numAffected":1,"numAtRisk":107}]},{"term":"Urosepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v27.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":453},{"groupId":"EG001","numAffected":0,"numAtRisk":225},{"groupId":"EG002","numAffected":1,"numAtRisk":96},{"groupId":"EG003","numAffected":0,"numAtRisk":107}]},{"term":"Femur fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA v27.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":453},{"groupId":"EG001","numAffected":0,"numAtRisk":225},{"groupId":"EG002","numAffected":0,"numAtRisk":96},{"groupId":"EG003","numAffected":1,"numAtRisk":107}]},{"term":"Joint injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA v27.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":453},{"groupId":"EG001","numAffected":0,"numAtRisk":225},{"groupId":"EG002","numAffected":0,"numAtRisk":96},{"groupId":"EG003","numAffected":1,"numAtRisk":107}]},{"term":"Rib fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA v27.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":453},{"groupId":"EG001","numAffected":0,"numAtRisk":225},{"groupId":"EG002","numAffected":0,"numAtRisk":96},{"groupId":"EG003","numAffected":1,"numAtRisk":107}]},{"term":"Sternal fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA v27.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":453},{"groupId":"EG001","numAffected":0,"numAtRisk":225},{"groupId":"EG002","numAffected":0,"numAtRisk":96},{"groupId":"EG003","numAffected":1,"numAtRisk":107}]},{"term":"Subdural haematoma","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA v27.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":453},{"groupId":"EG001","numAffected":0,"numAtRisk":225},{"groupId":"EG002","numAffected":1,"numAtRisk":96},{"groupId":"EG003","numAffected":0,"numAtRisk":107}]},{"term":"Hypervolaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA v27.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":453},{"groupId":"EG001","numAffected":0,"numAtRisk":225},{"groupId":"EG002","numAffected":1,"numAtRisk":96},{"groupId":"EG003","numAffected":0,"numAtRisk":107}]},{"term":"Lung adenocarcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA v27.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":453},{"groupId":"EG001","numAffected":0,"numAtRisk":225},{"groupId":"EG002","numAffected":0,"numAtRisk":96},{"groupId":"EG003","numAffected":1,"numAtRisk":107}]},{"term":"Syncope","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA v27.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":453},{"groupId":"EG001","numAffected":0,"numAtRisk":225},{"groupId":"EG002","numAffected":0,"numAtRisk":96},{"groupId":"EG003","numAffected":1,"numAtRisk":107}]},{"term":"Azotaemia","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA v27.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":453},{"groupId":"EG001","numAffected":0,"numAtRisk":225},{"groupId":"EG002","numAffected":0,"numAtRisk":96},{"groupId":"EG003","numAffected":1,"numAtRisk":107}]},{"term":"Pneumothorax","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v27.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":453},{"groupId":"EG001","numAffected":0,"numAtRisk":225},{"groupId":"EG002","numAffected":0,"numAtRisk":96},{"groupId":"EG003","numAffected":1,"numAtRisk":107}]},{"term":"Subcutaneous emphysema","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA v27.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":453},{"groupId":"EG001","numAffected":0,"numAtRisk":225},{"groupId":"EG002","numAffected":0,"numAtRisk":96},{"groupId":"EG003","numAffected":1,"numAtRisk":107}]},{"term":"Deep vein thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA v27.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":453},{"groupId":"EG001","numAffected":0,"numAtRisk":225},{"groupId":"EG002","numAffected":1,"numAtRisk":96},{"groupId":"EG003","numAffected":1,"numAtRisk":107}]},{"term":"Haematoma","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA v27.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":453},{"groupId":"EG001","numAffected":0,"numAtRisk":225},{"groupId":"EG002","numAffected":1,"numAtRisk":96},{"groupId":"EG003","numAffected":0,"numAtRisk":107}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA v27.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":453},{"groupId":"EG001","numAffected":0,"numAtRisk":225},{"groupId":"EG002","numAffected":1,"numAtRisk":96},{"groupId":"EG003","numAffected":0,"numAtRisk":107}]},{"term":"Hypertensive crisis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA v27.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":453},{"groupId":"EG001","numAffected":0,"numAtRisk":225},{"groupId":"EG002","numAffected":1,"numAtRisk":96},{"groupId":"EG003","numAffected":0,"numAtRisk":107}]}],"otherEvents":[{"term":"Ear pain","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":453},{"groupId":"EG001","numAffected":0,"numAtRisk":225},{"groupId":"EG002","numAffected":0,"numAtRisk":96},{"groupId":"EG003","numAffected":0,"numAtRisk":107}]},{"term":"Meniere's disease","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":453},{"groupId":"EG001","numAffected":1,"numAtRisk":225},{"groupId":"EG002","numAffected":0,"numAtRisk":96},{"groupId":"EG003","numAffected":0,"numAtRisk":107}]},{"term":"Epiretinal membrane","organSystem":"Eye disorders","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":453},{"groupId":"EG001","numAffected":0,"numAtRisk":225},{"groupId":"EG002","numAffected":0,"numAtRisk":96},{"groupId":"EG003","numAffected":0,"numAtRisk":107}]},{"term":"Ocular hypertension","organSystem":"Eye disorders","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":453},{"groupId":"EG001","numAffected":0,"numAtRisk":225},{"groupId":"EG002","numAffected":0,"numAtRisk":96},{"groupId":"EG003","numAffected":0,"numAtRisk":107}]},{"term":"Vitreous haemorrhage","organSystem":"Eye disorders","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":453},{"groupId":"EG001","numAffected":0,"numAtRisk":225},{"groupId":"EG002","numAffected":0,"numAtRisk":96},{"groupId":"EG003","numAffected":0,"numAtRisk":107}]},{"term":"Fatigue (FATIGUE)","organSystem":"General disorders","sourceVocabulary":"MedDRA v26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":168,"numAtRisk":453},{"groupId":"EG001","numAffected":86,"numAtRisk":225},{"groupId":"EG002","numAffected":52,"numAtRisk":96},{"groupId":"EG003","numAffected":62,"numAtRisk":107}]},{"term":"Injection site pain (PAIN AT INJECTION SITE)","organSystem":"General disorders","sourceVocabulary":"MedDRA v26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":159,"numAtRisk":453},{"groupId":"EG001","numAffected":24,"numAtRisk":225},{"groupId":"EG002","numAffected":54,"numAtRisk":96},{"groupId":"EG003","numAffected":41,"numAtRisk":107}]},{"term":"Oedema peripheral","organSystem":"General disorders","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":453},{"groupId":"EG001","numAffected":1,"numAtRisk":225},{"groupId":"EG002","numAffected":0,"numAtRisk":96},{"groupId":"EG003","numAffected":0,"numAtRisk":107}]},{"term":"Pyrexia (FEVER)","organSystem":"General disorders","sourceVocabulary":"MedDRA v26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":453},{"groupId":"EG001","numAffected":3,"numAtRisk":225},{"groupId":"EG002","numAffected":1,"numAtRisk":96},{"groupId":"EG003","numAffected":1,"numAtRisk":107}]},{"term":"Swelling (SWELLING)","organSystem":"General disorders","sourceVocabulary":"MedDRA v26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":32,"numAtRisk":453},{"groupId":"EG001","numAffected":2,"numAtRisk":225},{"groupId":"EG002","numAffected":9,"numAtRisk":96},{"groupId":"EG003","numAffected":12,"numAtRisk":107}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":453},{"groupId":"EG001","numAffected":0,"numAtRisk":225},{"groupId":"EG002","numAffected":1,"numAtRisk":96},{"groupId":"EG003","numAffected":0,"numAtRisk":107}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":453},{"groupId":"EG001","numAffected":0,"numAtRisk":225},{"groupId":"EG002","numAffected":0,"numAtRisk":96},{"groupId":"EG003","numAffected":0,"numAtRisk":107}]},{"term":"Diarrhoea (DIARRHEA)","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":67,"numAtRisk":453},{"groupId":"EG001","numAffected":38,"numAtRisk":225},{"groupId":"EG002","numAffected":28,"numAtRisk":96},{"groupId":"EG003","numAffected":27,"numAtRisk":107}]},{"term":"Food poisoning","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":453},{"groupId":"EG001","numAffected":0,"numAtRisk":225},{"groupId":"EG002","numAffected":0,"numAtRisk":96},{"groupId":"EG003","numAffected":0,"numAtRisk":107}]},{"term":"Gastritis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":453},{"groupId":"EG001","numAffected":1,"numAtRisk":225},{"groupId":"EG002","numAffected":0,"numAtRisk":96},{"groupId":"EG003","numAffected":0,"numAtRisk":107}]},{"term":"Irritable bowel syndrome","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":453},{"groupId":"EG001","numAffected":1,"numAtRisk":225},{"groupId":"EG002","numAffected":0,"numAtRisk":96},{"groupId":"EG003","numAffected":0,"numAtRisk":107}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":453},{"groupId":"EG001","numAffected":1,"numAtRisk":225},{"groupId":"EG002","numAffected":0,"numAtRisk":96},{"groupId":"EG003","numAffected":0,"numAtRisk":107}]},{"term":"Nausea (NAUSEA)","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":53,"numAtRisk":453},{"groupId":"EG001","numAffected":23,"numAtRisk":225},{"groupId":"EG002","numAffected":15,"numAtRisk":96},{"groupId":"EG003","numAffected":13,"numAtRisk":107}]},{"term":"Vomiting (VOMITING)","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":9,"numAtRisk":453},{"groupId":"EG001","numAffected":3,"numAtRisk":225},{"groupId":"EG002","numAffected":5,"numAtRisk":96},{"groupId":"EG003","numAffected":2,"numAtRisk":107}]},{"term":"Primary biliary cholangitis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":453},{"groupId":"EG001","numAffected":0,"numAtRisk":225},{"groupId":"EG002","numAffected":0,"numAtRisk":96},{"groupId":"EG003","numAffected":0,"numAtRisk":107}]},{"term":"Seasonal allergy","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":453},{"groupId":"EG001","numAffected":0,"numAtRisk":225},{"groupId":"EG002","numAffected":0,"numAtRisk":96},{"groupId":"EG003","numAffected":0,"numAtRisk":107}]},{"term":"COVID-19","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":453},{"groupId":"EG001","numAffected":3,"numAtRisk":225},{"groupId":"EG002","numAffected":1,"numAtRisk":96},{"groupId":"EG003","numAffected":2,"numAtRisk":107}]},{"term":"Bronchitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":453},{"groupId":"EG001","numAffected":0,"numAtRisk":225},{"groupId":"EG002","numAffected":0,"numAtRisk":96},{"groupId":"EG003","numAffected":0,"numAtRisk":107}]},{"term":"Campylobacter infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":453},{"groupId":"EG001","numAffected":0,"numAtRisk":225},{"groupId":"EG002","numAffected":0,"numAtRisk":96},{"groupId":"EG003","numAffected":0,"numAtRisk":107}]},{"term":"Gastroenteritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":453},{"groupId":"EG001","numAffected":0,"numAtRisk":225},{"groupId":"EG002","numAffected":0,"numAtRisk":96},{"groupId":"EG003","numAffected":0,"numAtRisk":107}]},{"term":"Localised infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":453},{"groupId":"EG001","numAffected":1,"numAtRisk":225},{"groupId":"EG002","numAffected":0,"numAtRisk":96},{"groupId":"EG003","numAffected":0,"numAtRisk":107}]},{"term":"Otitis externa","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":453},{"groupId":"EG001","numAffected":1,"numAtRisk":225},{"groupId":"EG002","numAffected":0,"numAtRisk":96},{"groupId":"EG003","numAffected":0,"numAtRisk":107}]},{"term":"Otitis media","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":453},{"groupId":"EG001","numAffected":1,"numAtRisk":225},{"groupId":"EG002","numAffected":0,"numAtRisk":96},{"groupId":"EG003","numAffected":1,"numAtRisk":107}]},{"term":"Sinusitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":453},{"groupId":"EG001","numAffected":1,"numAtRisk":225},{"groupId":"EG002","numAffected":0,"numAtRisk":96},{"groupId":"EG003","numAffected":0,"numAtRisk":107}]},{"term":"Tinea cruris","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":453},{"groupId":"EG001","numAffected":0,"numAtRisk":225},{"groupId":"EG002","numAffected":0,"numAtRisk":96},{"groupId":"EG003","numAffected":0,"numAtRisk":107}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":453},{"groupId":"EG001","numAffected":2,"numAtRisk":225},{"groupId":"EG002","numAffected":2,"numAtRisk":96},{"groupId":"EG003","numAffected":5,"numAtRisk":107}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":453},{"groupId":"EG001","numAffected":4,"numAtRisk":225},{"groupId":"EG002","numAffected":2,"numAtRisk":96},{"groupId":"EG003","numAffected":2,"numAtRisk":107}]},{"term":"Contusion","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":453},{"groupId":"EG001","numAffected":0,"numAtRisk":225},{"groupId":"EG002","numAffected":0,"numAtRisk":96},{"groupId":"EG003","numAffected":1,"numAtRisk":107}]},{"term":"Eye contusion","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":453},{"groupId":"EG001","numAffected":0,"numAtRisk":225},{"groupId":"EG002","numAffected":0,"numAtRisk":96},{"groupId":"EG003","numAffected":0,"numAtRisk":107}]},{"term":"Eye injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":453},{"groupId":"EG001","numAffected":0,"numAtRisk":225},{"groupId":"EG002","numAffected":0,"numAtRisk":96},{"groupId":"EG003","numAffected":0,"numAtRisk":107}]},{"term":"Fall","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":453},{"groupId":"EG001","numAffected":0,"numAtRisk":225},{"groupId":"EG002","numAffected":1,"numAtRisk":96},{"groupId":"EG003","numAffected":4,"numAtRisk":107}]},{"term":"Hepatobiliary procedural complication","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":453},{"groupId":"EG001","numAffected":0,"numAtRisk":225},{"groupId":"EG002","numAffected":0,"numAtRisk":96},{"groupId":"EG003","numAffected":0,"numAtRisk":107}]},{"term":"Hyphaema","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":453},{"groupId":"EG001","numAffected":0,"numAtRisk":225},{"groupId":"EG002","numAffected":0,"numAtRisk":96},{"groupId":"EG003","numAffected":0,"numAtRisk":107}]},{"term":"Joint injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":453},{"groupId":"EG001","numAffected":0,"numAtRisk":225},{"groupId":"EG002","numAffected":0,"numAtRisk":96},{"groupId":"EG003","numAffected":0,"numAtRisk":107}]},{"term":"Ligament sprain","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":453},{"groupId":"EG001","numAffected":0,"numAtRisk":225},{"groupId":"EG002","numAffected":0,"numAtRisk":96},{"groupId":"EG003","numAffected":0,"numAtRisk":107}]},{"term":"Muscle rupture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":453},{"groupId":"EG001","numAffected":0,"numAtRisk":225},{"groupId":"EG002","numAffected":0,"numAtRisk":96},{"groupId":"EG003","numAffected":0,"numAtRisk":107}]},{"term":"Weight decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":453},{"groupId":"EG001","numAffected":1,"numAtRisk":225},{"groupId":"EG002","numAffected":0,"numAtRisk":96},{"groupId":"EG003","numAffected":0,"numAtRisk":107}]},{"term":"White blood cell count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":453},{"groupId":"EG001","numAffected":1,"numAtRisk":225},{"groupId":"EG002","numAffected":0,"numAtRisk":96},{"groupId":"EG003","numAffected":0,"numAtRisk":107}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":453},{"groupId":"EG001","numAffected":0,"numAtRisk":225},{"groupId":"EG002","numAffected":0,"numAtRisk":96},{"groupId":"EG003","numAffected":0,"numAtRisk":107}]},{"term":"Gout","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":453},{"groupId":"EG001","numAffected":0,"numAtRisk":225},{"groupId":"EG002","numAffected":0,"numAtRisk":96},{"groupId":"EG003","numAffected":0,"numAtRisk":107}]},{"term":"Hyperlipidaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":453},{"groupId":"EG001","numAffected":0,"numAtRisk":225},{"groupId":"EG002","numAffected":0,"numAtRisk":96},{"groupId":"EG003","numAffected":0,"numAtRisk":107}]},{"term":"Hypokalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":453},{"groupId":"EG001","numAffected":1,"numAtRisk":225},{"groupId":"EG002","numAffected":0,"numAtRisk":96},{"groupId":"EG003","numAffected":0,"numAtRisk":107}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":453},{"groupId":"EG001","numAffected":1,"numAtRisk":225},{"groupId":"EG002","numAffected":0,"numAtRisk":96},{"groupId":"EG003","numAffected":0,"numAtRisk":107}]},{"term":"Type 2 diabetes mellitus","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":453},{"groupId":"EG001","numAffected":1,"numAtRisk":225},{"groupId":"EG002","numAffected":0,"numAtRisk":96},{"groupId":"EG003","numAffected":1,"numAtRisk":107}]},{"term":"Arthralgia (JOINT PAIN)","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA v26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":56,"numAtRisk":453},{"groupId":"EG001","numAffected":23,"numAtRisk":225},{"groupId":"EG002","numAffected":21,"numAtRisk":96},{"groupId":"EG003","numAffected":27,"numAtRisk":107}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":453},{"groupId":"EG001","numAffected":1,"numAtRisk":225},{"groupId":"EG002","numAffected":0,"numAtRisk":96},{"groupId":"EG003","numAffected":0,"numAtRisk":107}]},{"term":"Muscle spasms","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":453},{"groupId":"EG001","numAffected":0,"numAtRisk":225},{"groupId":"EG002","numAffected":0,"numAtRisk":96},{"groupId":"EG003","numAffected":0,"numAtRisk":107}]},{"term":"Myalgia (MUSCLE PAIN)","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA v26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":110,"numAtRisk":453},{"groupId":"EG001","numAffected":36,"numAtRisk":225},{"groupId":"EG002","numAffected":32,"numAtRisk":96},{"groupId":"EG003","numAffected":33,"numAtRisk":107}]},{"term":"Osteoarthritis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":453},{"groupId":"EG001","numAffected":1,"numAtRisk":225},{"groupId":"EG002","numAffected":0,"numAtRisk":96},{"groupId":"EG003","numAffected":0,"numAtRisk":107}]},{"term":"Tendonitis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":453},{"groupId":"EG001","numAffected":0,"numAtRisk":225},{"groupId":"EG002","numAffected":0,"numAtRisk":96},{"groupId":"EG003","numAffected":0,"numAtRisk":107}]},{"term":"Bell's palsy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":453},{"groupId":"EG001","numAffected":0,"numAtRisk":225},{"groupId":"EG002","numAffected":0,"numAtRisk":96},{"groupId":"EG003","numAffected":0,"numAtRisk":107}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":453},{"groupId":"EG001","numAffected":1,"numAtRisk":225},{"groupId":"EG002","numAffected":0,"numAtRisk":96},{"groupId":"EG003","numAffected":0,"numAtRisk":107}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":453},{"groupId":"EG001","numAffected":1,"numAtRisk":225},{"groupId":"EG002","numAffected":0,"numAtRisk":96},{"groupId":"EG003","numAffected":1,"numAtRisk":107}]},{"term":"Headache (HEADACHE)","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA v26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":128,"numAtRisk":453},{"groupId":"EG001","numAffected":68,"numAtRisk":225},{"groupId":"EG002","numAffected":42,"numAtRisk":96},{"groupId":"EG003","numAffected":38,"numAtRisk":107}]},{"term":"Migraine","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":453},{"groupId":"EG001","numAffected":1,"numAtRisk":225},{"groupId":"EG002","numAffected":3,"numAtRisk":96},{"groupId":"EG003","numAffected":0,"numAtRisk":107}]},{"term":"Seizure","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":453},{"groupId":"EG001","numAffected":1,"numAtRisk":225},{"groupId":"EG002","numAffected":0,"numAtRisk":96},{"groupId":"EG003","numAffected":0,"numAtRisk":107}]},{"term":"Attention deficit hyperactivity disorder","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":453},{"groupId":"EG001","numAffected":0,"numAtRisk":225},{"groupId":"EG002","numAffected":0,"numAtRisk":96},{"groupId":"EG003","numAffected":0,"numAtRisk":107}]},{"term":"Depression","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":453},{"groupId":"EG001","numAffected":0,"numAtRisk":225},{"groupId":"EG002","numAffected":0,"numAtRisk":96},{"groupId":"EG003","numAffected":0,"numAtRisk":107}]},{"term":"Schizophrenia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":453},{"groupId":"EG001","numAffected":1,"numAtRisk":225},{"groupId":"EG002","numAffected":0,"numAtRisk":96},{"groupId":"EG003","numAffected":0,"numAtRisk":107}]},{"term":"Cystitis haemorrhagic","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":453},{"groupId":"EG001","numAffected":0,"numAtRisk":225},{"groupId":"EG002","numAffected":0,"numAtRisk":96},{"groupId":"EG003","numAffected":0,"numAtRisk":107}]},{"term":"Hydronephrosis","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":453},{"groupId":"EG001","numAffected":1,"numAtRisk":225},{"groupId":"EG002","numAffected":0,"numAtRisk":96},{"groupId":"EG003","numAffected":0,"numAtRisk":107}]},{"term":"Asthma","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":453},{"groupId":"EG001","numAffected":1,"numAtRisk":225},{"groupId":"EG002","numAffected":0,"numAtRisk":96},{"groupId":"EG003","numAffected":0,"numAtRisk":107}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":453},{"groupId":"EG001","numAffected":1,"numAtRisk":225},{"groupId":"EG002","numAffected":0,"numAtRisk":96},{"groupId":"EG003","numAffected":0,"numAtRisk":107}]},{"term":"Emphysema","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":453},{"groupId":"EG001","numAffected":1,"numAtRisk":225},{"groupId":"EG002","numAffected":0,"numAtRisk":96},{"groupId":"EG003","numAffected":0,"numAtRisk":107}]},{"term":"Epistaxis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":453},{"groupId":"EG001","numAffected":0,"numAtRisk":225},{"groupId":"EG002","numAffected":0,"numAtRisk":96},{"groupId":"EG003","numAffected":0,"numAtRisk":107}]},{"term":"Oropharyngeal pain","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":453},{"groupId":"EG001","numAffected":1,"numAtRisk":225},{"groupId":"EG002","numAffected":0,"numAtRisk":96},{"groupId":"EG003","numAffected":0,"numAtRisk":107}]},{"term":"Respiratory disorder","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":453},{"groupId":"EG001","numAffected":0,"numAtRisk":225},{"groupId":"EG002","numAffected":0,"numAtRisk":96},{"groupId":"EG003","numAffected":0,"numAtRisk":107}]},{"term":"Respiratory tract congestion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":453},{"groupId":"EG001","numAffected":2,"numAtRisk":225},{"groupId":"EG002","numAffected":0,"numAtRisk":96},{"groupId":"EG003","numAffected":0,"numAtRisk":107}]},{"term":"Sinus congestion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":453},{"groupId":"EG001","numAffected":1,"numAtRisk":225},{"groupId":"EG002","numAffected":0,"numAtRisk":96},{"groupId":"EG003","numAffected":0,"numAtRisk":107}]},{"term":"Erythema (REDNESS)","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA v26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":27,"numAtRisk":453},{"groupId":"EG001","numAffected":1,"numAtRisk":225},{"groupId":"EG002","numAffected":7,"numAtRisk":96},{"groupId":"EG003","numAffected":8,"numAtRisk":107}]},{"term":"Perioral dermatitis","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":453},{"groupId":"EG001","numAffected":0,"numAtRisk":225},{"groupId":"EG002","numAffected":0,"numAtRisk":96},{"groupId":"EG003","numAffected":0,"numAtRisk":107}]},{"term":"Urticaria","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":453},{"groupId":"EG001","numAffected":0,"numAtRisk":225},{"groupId":"EG002","numAffected":0,"numAtRisk":96},{"groupId":"EG003","numAffected":0,"numAtRisk":107}]},{"term":"Physical assault","organSystem":"Social circumstances","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":453},{"groupId":"EG001","numAffected":0,"numAtRisk":225},{"groupId":"EG002","numAffected":0,"numAtRisk":96},{"groupId":"EG003","numAffected":0,"numAtRisk":107}]},{"term":"Bleeding varicose vein","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":453},{"groupId":"EG001","numAffected":0,"numAtRisk":225},{"groupId":"EG002","numAffected":0,"numAtRisk":96},{"groupId":"EG003","numAffected":0,"numAtRisk":107}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":453},{"groupId":"EG001","numAffected":1,"numAtRisk":225},{"groupId":"EG002","numAffected":1,"numAtRisk":96},{"groupId":"EG003","numAffected":0,"numAtRisk":107}]},{"term":"Hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA v26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":453},{"groupId":"EG001","numAffected":0,"numAtRisk":225},{"groupId":"EG002","numAffected":0,"numAtRisk":96},{"groupId":"EG003","numAffected":0,"numAtRisk":107}]},{"term":"Nephrogenic anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA v27.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":453},{"groupId":"EG001","numAffected":0,"numAtRisk":225},{"groupId":"EG002","numAffected":0,"numAtRisk":96},{"groupId":"EG003","numAffected":1,"numAtRisk":107}]},{"term":"Atrial fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA v27.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":453},{"groupId":"EG001","numAffected":0,"numAtRisk":225},{"groupId":"EG002","numAffected":0,"numAtRisk":96},{"groupId":"EG003","numAffected":2,"numAtRisk":107}]},{"term":"Atrial flutter","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA v27.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":453},{"groupId":"EG001","numAffected":0,"numAtRisk":225},{"groupId":"EG002","numAffected":0,"numAtRisk":96},{"groupId":"EG003","numAffected":1,"numAtRisk":107}]},{"term":"Bundle branch block left","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA v27.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":453},{"groupId":"EG001","numAffected":0,"numAtRisk":225},{"groupId":"EG002","numAffected":0,"numAtRisk":96},{"groupId":"EG003","numAffected":1,"numAtRisk":107}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v27.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":453},{"groupId":"EG001","numAffected":0,"numAtRisk":225},{"groupId":"EG002","numAffected":1,"numAtRisk":96},{"groupId":"EG003","numAffected":0,"numAtRisk":107}]},{"term":"Haematochezia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v27.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":453},{"groupId":"EG001","numAffected":0,"numAtRisk":225},{"groupId":"EG002","numAffected":0,"numAtRisk":96},{"groupId":"EG003","numAffected":1,"numAtRisk":107}]},{"term":"Impaired healing","organSystem":"General disorders","sourceVocabulary":"MedDRA v27.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":453},{"groupId":"EG001","numAffected":0,"numAtRisk":225},{"groupId":"EG002","numAffected":0,"numAtRisk":96},{"groupId":"EG003","numAffected":1,"numAtRisk":107}]},{"term":"Non-cardiac chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA v27.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":453},{"groupId":"EG001","numAffected":0,"numAtRisk":225},{"groupId":"EG002","numAffected":1,"numAtRisk":96},{"groupId":"EG003","numAffected":0,"numAtRisk":107}]},{"term":"Candida infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v27.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":453},{"groupId":"EG001","numAffected":0,"numAtRisk":225},{"groupId":"EG002","numAffected":0,"numAtRisk":96},{"groupId":"EG003","numAffected":1,"numAtRisk":107}]},{"term":"Cellulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v27.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":453},{"groupId":"EG001","numAffected":0,"numAtRisk":225},{"groupId":"EG002","numAffected":1,"numAtRisk":96},{"groupId":"EG003","numAffected":3,"numAtRisk":107}]},{"term":"Cytomegalovirus infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v27.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":453},{"groupId":"EG001","numAffected":0,"numAtRisk":225},{"groupId":"EG002","numAffected":1,"numAtRisk":96},{"groupId":"EG003","numAffected":0,"numAtRisk":107}]},{"term":"Cytomegalovirus viraemia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v27.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":453},{"groupId":"EG001","numAffected":0,"numAtRisk":225},{"groupId":"EG002","numAffected":0,"numAtRisk":96},{"groupId":"EG003","numAffected":1,"numAtRisk":107}]},{"term":"Herpes zoster","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v27.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":453},{"groupId":"EG001","numAffected":0,"numAtRisk":225},{"groupId":"EG002","numAffected":0,"numAtRisk":96},{"groupId":"EG003","numAffected":1,"numAtRisk":107}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v27.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":453},{"groupId":"EG001","numAffected":0,"numAtRisk":225},{"groupId":"EG002","numAffected":0,"numAtRisk":96},{"groupId":"EG003","numAffected":1,"numAtRisk":107}]},{"term":"Pharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v27.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":453},{"groupId":"EG001","numAffected":0,"numAtRisk":225},{"groupId":"EG002","numAffected":1,"numAtRisk":96},{"groupId":"EG003","numAffected":0,"numAtRisk":107}]},{"term":"Abdominal injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA v27.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":453},{"groupId":"EG001","numAffected":0,"numAtRisk":225},{"groupId":"EG002","numAffected":0,"numAtRisk":96},{"groupId":"EG003","numAffected":1,"numAtRisk":107}]},{"term":"Cervical vertebral fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA v27.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":453},{"groupId":"EG001","numAffected":0,"numAtRisk":225},{"groupId":"EG002","numAffected":0,"numAtRisk":96},{"groupId":"EG003","numAffected":1,"numAtRisk":107}]},{"term":"Craniocerebral injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA v27.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":453},{"groupId":"EG001","numAffected":0,"numAtRisk":225},{"groupId":"EG002","numAffected":0,"numAtRisk":96},{"groupId":"EG003","numAffected":1,"numAtRisk":107}]},{"term":"Head injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA v27.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":453},{"groupId":"EG001","numAffected":0,"numAtRisk":225},{"groupId":"EG002","numAffected":1,"numAtRisk":96},{"groupId":"EG003","numAffected":0,"numAtRisk":107}]},{"term":"Road traffic accident","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA v27.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":453},{"groupId":"EG001","numAffected":0,"numAtRisk":225},{"groupId":"EG002","numAffected":0,"numAtRisk":96},{"groupId":"EG003","numAffected":1,"numAtRisk":107}]},{"term":"Skin laceration","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA v27.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":453},{"groupId":"EG001","numAffected":0,"numAtRisk":225},{"groupId":"EG002","numAffected":0,"numAtRisk":96},{"groupId":"EG003","numAffected":1,"numAtRisk":107}]},{"term":"Computerised tomogram abnormal","organSystem":"Investigations","sourceVocabulary":"MedDRA v27.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":453},{"groupId":"EG001","numAffected":0,"numAtRisk":225},{"groupId":"EG002","numAffected":0,"numAtRisk":96},{"groupId":"EG003","numAffected":1,"numAtRisk":107}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA v27.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":453},{"groupId":"EG001","numAffected":0,"numAtRisk":225},{"groupId":"EG002","numAffected":0,"numAtRisk":96},{"groupId":"EG003","numAffected":1,"numAtRisk":107}]},{"term":"Musculoskeletal chest pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA v27.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":453},{"groupId":"EG001","numAffected":0,"numAtRisk":225},{"groupId":"EG002","numAffected":0,"numAtRisk":96},{"groupId":"EG003","numAffected":1,"numAtRisk":107}]},{"term":"Osteonecrosis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA v27.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":453},{"groupId":"EG001","numAffected":0,"numAtRisk":225},{"groupId":"EG002","numAffected":0,"numAtRisk":96},{"groupId":"EG003","numAffected":1,"numAtRisk":107}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA v27.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":453},{"groupId":"EG001","numAffected":0,"numAtRisk":225},{"groupId":"EG002","numAffected":0,"numAtRisk":96},{"groupId":"EG003","numAffected":1,"numAtRisk":107}]},{"term":"Basal cell carcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA v27.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":453},{"groupId":"EG001","numAffected":0,"numAtRisk":225},{"groupId":"EG002","numAffected":0,"numAtRisk":96},{"groupId":"EG003","numAffected":1,"numAtRisk":107}]},{"term":"Renal cell carcinoma stage IV","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA v27.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":453},{"groupId":"EG001","numAffected":0,"numAtRisk":225},{"groupId":"EG002","numAffected":1,"numAtRisk":96},{"groupId":"EG003","numAffected":0,"numAtRisk":107}]},{"term":"Cerebral ischaemia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA v27.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":453},{"groupId":"EG001","numAffected":0,"numAtRisk":225},{"groupId":"EG002","numAffected":0,"numAtRisk":96},{"groupId":"EG003","numAffected":1,"numAtRisk":107}]},{"term":"Syncope","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA v27.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":453},{"groupId":"EG001","numAffected":0,"numAtRisk":225},{"groupId":"EG002","numAffected":1,"numAtRisk":96},{"groupId":"EG003","numAffected":1,"numAtRisk":107}]},{"term":"Vertebral artery occlusion","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA v27.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":453},{"groupId":"EG001","numAffected":0,"numAtRisk":225},{"groupId":"EG002","numAffected":0,"numAtRisk":96},{"groupId":"EG003","numAffected":1,"numAtRisk":107}]},{"term":"Acute kidney injury","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA v27.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":453},{"groupId":"EG001","numAffected":0,"numAtRisk":225},{"groupId":"EG002","numAffected":0,"numAtRisk":96},{"groupId":"EG003","numAffected":1,"numAtRisk":107}]},{"term":"Prostatitis","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA v27.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":453},{"groupId":"EG001","numAffected":0,"numAtRisk":225},{"groupId":"EG002","numAffected":1,"numAtRisk":96},{"groupId":"EG003","numAffected":0,"numAtRisk":107}]},{"term":"Atelectasis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v27.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":453},{"groupId":"EG001","numAffected":0,"numAtRisk":225},{"groupId":"EG002","numAffected":0,"numAtRisk":96},{"groupId":"EG003","numAffected":1,"numAtRisk":107}]},{"term":"Dermatitis contact","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA v27.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":453},{"groupId":"EG001","numAffected":0,"numAtRisk":225},{"groupId":"EG002","numAffected":1,"numAtRisk":96},{"groupId":"EG003","numAffected":0,"numAtRisk":107}]},{"term":"Eczema","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA v27.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":453},{"groupId":"EG001","numAffected":0,"numAtRisk":225},{"groupId":"EG002","numAffected":0,"numAtRisk":96},{"groupId":"EG003","numAffected":1,"numAtRisk":107}]},{"term":"Haematoma","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA v27.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":453},{"groupId":"EG001","numAffected":0,"numAtRisk":225},{"groupId":"EG002","numAffected":0,"numAtRisk":96},{"groupId":"EG003","numAffected":1,"numAtRisk":107}]},{"term":"Superior vena cava syndrome","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA v27.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":453},{"groupId":"EG001","numAffected":0,"numAtRisk":225},{"groupId":"EG002","numAffected":1,"numAtRisk":96},{"groupId":"EG003","numAffected":0,"numAtRisk":107}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results."},"pointOfContact":{"title":"Pfizer ClinicalTrials.gov Call Center","organization":"Pfizer Inc","email":"ClinicalTrials.gov_Inquires@pfizer.com","phone":"1-800-718-1021"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot","hasProtocol":true,"hasSap":false,"hasIcf":false,"label":"Study Protocol","date":"2023-08-21","uploadDate":"2025-03-03T15:58","filename":"Prot_000.pdf","size":16254455},{"typeAbbrev":"SAP","hasProtocol":false,"hasSap":true,"hasIcf":false,"label":"Statistical Analysis Plan","date":"2023-09-06","uploadDate":"2025-03-03T15:59","filename":"SAP_001.pdf","size":431697}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-11-09","submissionTracking":{"firstMcpInfo":{"postDateStruct":{"date":"2025-03-25","type":"ACTUAL"}}}}},"hasResults":true}